CLARIVATE PLC, 10-K filed on 2/19/2025
Annual Report
v3.25.0.1
Cover - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Jan. 31, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-38911    
Entity Registrant Name CLARIVATE PLC    
Entity Incorporation, State or Country Code Y9    
Entity Address, Address Line One 70 St. Mary Axe    
Entity Address, City or Town London    
Entity Address, Postal Zip Code EC3A 8BE    
Entity Address, Country GB    
Country Region 44    
City Area Code 207    
Local Phone Number 4334000    
Title of 12(b) Security Ordinary Shares, no par value    
Trading Symbol CLVT    
Security Exchange Name NYSE    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding   691,638,374  
Entity Central Index Key 0001764046    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Entity Tax Identification Number 00-0000000    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Public Float     $ 1,800.0
v3.25.0.1
Audit Information
12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Firm ID 238
Auditor Name PricewaterhouseCoopers LLP
Auditor Location Philadelphia, Pennsylvania
v3.25.0.1
Cover
12 Months Ended
Dec. 31, 2024
Cover [Abstract]  
Documents Incorporated by Reference
The information required by Part III of this Form 10-K, to the extent not set forth herein, is incorporated herein by reference to the registrant’s definitive proxy statement on Schedule 14A for the 2025 Annual General Meeting of Shareholders, to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the close of the registrant’s fiscal year.
v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents, including restricted cash $ 295.2 $ 370.7
Accounts receivable, net 798.3 908.3
Prepaid expenses 85.9 88.5
Other current assets 65.2 68.0
Assets held for sale 0.0 26.7
Total current assets 1,244.6 1,462.2
Property and equipment, net 53.5 51.6
Other intangible assets, net 8,441.2 9,006.6
Goodwill 1,566.6 2,023.7
Other non-current assets 82.2 60.8
Deferred income taxes 48.5 46.7
Operating lease right-of-use assets 53.6 55.2
Total assets 11,490.2 12,706.8
Current liabilities:    
Accounts payable 124.5 144.1
Accrued compensation 119.2 126.5
Accrued expenses and other current liabilities 310.1 315.2
Current portion of deferred revenues 859.1 983.1
Current portion of operating lease liability 20.6 24.4
Liabilities held for sale 0.0 6.7
Total current liabilities 1,433.5 1,600.0
Long-term debt 4,518.7 4,721.1
Non-current portion of deferred revenues 16.6 38.7
Other non-current liabilities 55.9 41.9
Deferred income taxes 273.3 249.6
Operating lease liabilities 53.2 63.2
Total liabilities 6,351.2 6,714.5
Commitments and contingencies (Note 17)
Shareholders' equity:    
Preferred Shares, no par value; 14.4 shares authorized; 5.25% Mandatory Convertible Preferred Shares, Series A, zero and 14.4 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 0.0 1,392.6
Ordinary Shares, no par value; unlimited shares authorized; 691.4 and 666.1 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 12,978.8 11,740.5
Accumulated other comprehensive loss (526.3) (495.3)
Accumulated deficit (7,313.5) (6,645.5)
Total shareholders' equity 5,139.0 5,992.3
Total liabilities and shareholders' equity $ 11,490.2 $ 12,706.8
v3.25.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, authorized (in shares) 14,400,000 14,400,000
Preferred stock, dividend rate (as a percent) 5.25%  
Preferred stock, issued (in shares) 0 14,400,000
Preferred stock, outstanding (in shares) 0 14,400,000
Ordinary shares, par value (in dollars per share) $ 0 $ 0
Ordinary shares, issued (in shares) 691,400,000 666,100,000
Ordinary shares, outstanding (in shares) 691,400,000 666,100,000
v3.25.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Revenues $ 2,556.7 $ 2,628.8 $ 2,659.8
Operating Expenses:      
Cost of revenues 869.2 906.4 954.0
Selling, general and administrative costs 727.6 739.7 729.9
Depreciation and amortization 727.0 708.3 710.5
Goodwill and intangible asset impairments 540.7 979.9 4,449.1
Restructuring and other impairments 19.6 40.0 66.7
Other operating expense (income), net (51.8) (10.8) (324.8)
Total operating expenses 2,832.3 3,363.5 6,585.4
Income (loss) from operations (275.6) (734.7) (3,925.6)
Fair value adjustment of warrants (5.2) (15.9) (206.8)
Interest expense, net 283.4 293.7 270.3
Income (loss) before income tax (553.8) (1,012.5) (3,989.1)
Provision (benefit) for income taxes 82.9 (101.3) (28.9)
Net income (loss) (636.7) (911.2) (3,960.2)
Dividends on preferred shares 31.3 75.4 75.4
Net loss attributable to ordinary shares $ (668.0) $ (986.6) $ (4,035.6)
Per share      
Basic (in dollars per share) $ (0.96) $ (1.47) $ (5.97)
Diluted (in dollars per share) $ (0.96) $ (1.47) $ (6.24)
Weighted average shares used to compute earnings per share:      
Basic (in shares) 693.6 671.6 676.1
Diluted (in shares) 693.6 671.6 678.6
v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Net income (loss) $ (636.7) $ (911.2) $ (3,960.2)
Other comprehensive income (loss), net of tax:      
Interest rate swaps (5.5) (21.9) 37.0
Defined benefit pension plans, net of tax (0.8) (1.1) 2.9
Foreign currency translation adjustment (24.7) 193.6 (1,032.5)
Other comprehensive income (loss), net of tax (31.0) 170.6 (992.6)
Comprehensive income (loss) $ (667.7) $ (740.6) $ (4,952.8)
v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Statement of Comprehensive Income [Abstract]      
Interest rate swaps, tax $ (1.7) $ (7.2) $ 11.7
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax $ 0.8 $ 1.1 $ (2.9)
v3.25.0.1
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Millions
Total
Ordinary Shares
Preferred Shares
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Treasury Shares
Increase (Decrease) in Shareholders' Equity            
Treasury shares held (in shares)           500,000
Balance at beginning of the period (in shares) at Dec. 31, 2021   683,100,000 14,400,000      
Balance at beginning of the period at Dec. 31, 2021 $ 11,925.9 $ 11,827.9 $ 1,392.6 $ 326.7 $ (1,604.4) $ (16.9)
Increase (Decrease) in Shareholders' Equity            
Vesting of restricted stock units (in shares)   2,900,000        
Share-based award activity (in shares)   (1,300,000)        
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 83.2 $ 83.2        
Stock Repurchased and Retired During Period, Value 175.0 $ 167.3     7.7  
Dividends, Preferred Stock (75.4)       (75.4)  
Net income (loss) (3,960.2)       (3,960.2)  
Other comprehensive income (loss) (992.6)     (992.6)    
Balance at end of the period (in shares) at Dec. 31, 2022   674,400,000 14,400,000      
Balance at end of the period at Dec. 31, 2022 $ 6,812.5 $ 11,744.7 $ 1,392.6 (665.9) (5,658.9) $ 0.0
Increase (Decrease) in Shareholders' Equity            
Exercise of Private Placement Warrants (in shares)   (500,000)        
Exercise of stock options (in shares)   400,000        
Stock repurchased and retired (in shares)   (10,700,000)        
Repurchase of ordinary shares (in shares) (10,700,000)          
Stock repurchased and retired         (7.7)  
Sale of treasury shares (in shares) 500,000 500,000       (500,000)
Treasury stock sold at lower than repurchase price $ 5.7       (11.2) $ 16.9
Stock Issued During Period, Value, Stock Options Exercised 0.9 $ 0.9        
Treasury shares held (in shares)           0
Vesting of restricted stock units (in shares)   7,600,000        
Share-based award activity (in shares)   (2,400,000)        
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 94.2 $ 94.2        
Stock Repurchased and Retired During Period, Value (100.0) $ 100.0        
Dividends, Preferred Stock (75.4)       (75.4)  
Net income (loss) (911.2)       (911.2)  
Other comprehensive income (loss) 170.6     170.6    
Balance at end of the period (in shares) at Dec. 31, 2023   666,100,000 14,400,000      
Balance at end of the period at Dec. 31, 2023 $ 5,992.3 $ 11,740.5 $ 1,392.6 (495.3) (6,645.5) $ 0.0
Increase (Decrease) in Shareholders' Equity            
Exercise of stock options (in shares)   300,000        
Stock repurchased and retired (in shares) 13,800,000 (13,800,000)        
Stock Issued During Period, Value, Stock Options Exercised $ 1.6 $ 1.6        
Treasury shares held (in shares)           0
Vesting of restricted stock units (in shares)   6,700,000        
Share-based award activity (in shares)   (2,300,000)        
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition 45.7 $ 45.7        
Stock Repurchased and Retired During Period, Value 200.0 $ 200.0        
Dividends, Preferred Stock (31.3)       (31.3)  
Net income (loss) (636.7)       (636.7)  
Other comprehensive income (loss) (31.0)     (31.0)    
Balance at end of the period (in shares) at Dec. 31, 2024   691,400,000 0      
Balance at end of the period at Dec. 31, 2024 $ 5,139.0 $ 12,978.8 $ 0.0 $ (526.3) $ (7,313.5) $ 0.0
Increase (Decrease) in Shareholders' Equity            
Stock Issued During Period, Value, Conversion of Convertible Securities   $ 1,392.6 $ (1,392.6)      
Stock Issued During Period, Shares, Conversion of Convertible Securities   55,300,000 (14,400,000)      
Stock repurchased and retired (in shares) 34,400,000 (34,400,000)        
Treasury shares held (in shares)           0
v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash Flows From Operating Activities      
Net income (loss) $ (636.7) $ (911.2) $ (3,960.2)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation and amortization 727.0 708.3 710.5
Share-based compensation 59.9 109.0 93.9
Restructuring and other impairments, including goodwill 540.3 986.2 4,478.5
Fair value adjustment of warrants (5.2) (15.9) (206.8)
Gain on sale from divestitures (54.7) 0.0 (278.5)
Gain on legal settlement 0.0 (49.4) 0.0
Deferred income taxes 21.2 (78.4) (54.3)
Amortization of debt issuance costs 16.4 18.2 16.4
Other operating activities 3.3 37.8 (18.3)
Changes in operating assets and liabilities:      
Accounts receivable 92.6 (25.5) (28.3)
Prepaid expenses 1.5 1.7 (17.1)
Other assets (0.8) 35.1 (45.4)
Accounts payable (15.0) 41.2 (24.0)
Accrued expenses and other current liabilities 3.8 (44.4) (114.4)
Deferred revenues (106.2) 20.3 (9.3)
Operating leases, net (9.6) (8.0) (9.6)
Other liabilities 8.8 (80.8) (23.8)
Net cash provided by operating activities 646.6 744.2 509.3
Cash Flows From Investing Activities      
Capital expenditures (289.1) (242.5) (202.9)
Payments for acquisitions, net of cash acquired (32.0) (5.4) (24.8)
Proceeds from divestitures, net of cash divested 84.4 10.5 285.0
Net cash provided by (used for) investing activities (236.7) (237.4) 57.3
Cash Flows From Financing Activities      
Principal payments on term loans (198.1) (300.0) (321.5)
Repayments of revolving credit facility 0.0 0.0 (175.0)
Proceeds From Debt Issuance Costs   0.1  
Payment of debt issuance costs and discounts (20.1)   (2.1)
Payments for Repurchase of Equity 200.0 100.0 175.0
Cash dividends on preferred shares (37.7) (75.5) (75.4)
Payments related to tax withholding for share-based compensation (15.6) (20.6) (14.9)
Other financing activities 1.4 (0.5) 4.7
Net cash provided by (used for) financing activities (470.1) (496.5) (759.2)
Effects of exchange rates (15.3) 3.6 (38.2)
Net change in cash and cash equivalents, including restricted cash (75.5) 13.9 (230.8)
Cash and cash equivalents, including restricted cash, beginning of period 370.7 356.8 587.6
Cash and cash equivalents, including restricted cash, end of period 295.2 370.7 356.8
Cash paid for interest 265.3 273.5 251.5
Cash paid for income tax $ 52.9 $ 42.9 $ 63.7
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Nature of Operations and Summary of Significant Accounting Policies Nature of Operations and Summary of Significant Accounting Policies
Clarivate Plc (“Clarivate,” “us,” “we,” “our,” or the “Company”) is a public limited company incorporated under the laws of Jersey, Channel Islands.
We are a leading global provider of transformative intelligence. We connect people and organizations to the intelligence they can trust to transform their perspective, their work, and our world. We support the entire innovation lifecycle, from cultivating curiosity to protecting the world’s critical intellectual property assets. We offer enriched data, insights & analytics, workflow solutions, and expert services to our customers in the Academia & Government (“A&G”), Intellectual Property (“IP”), and Life Sciences & Healthcare (“LS&H”) end markets, which form the basis of our three reportable segments, organized by the different products and services we offer and the markets we serve. For additional information on our reportable segments, see Note 16 - Segment Information.
Basis of Presentation
The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include our accounts and the accounts of our wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Certain reclassifications of prior period amounts have been made to conform to the current period presentation.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the Consolidated Financial Statements and accompanying notes. Actual results could differ from those estimates. The most significant of these estimates relate to the initial valuation of acquired long-lived and intangible assets and goodwill, subsequent impairment analyses, and income taxes. We evaluate these estimates, assumptions, and judgments on an ongoing basis by reference to our historical experience and other factors, including expectations of future events that we believe are reasonable under the circumstances.
Concentration of Credit Risk
Accounts receivable are the primary financial instrument that potentially subjects us to significant concentrations of credit risk. Accounts receivable represent arrangements in which services were transferred to a customer before the customer pays consideration or before payment is due. We do not require collateral or other securities to support customer receivables. We perform ongoing credit evaluations of our customers and limit the amount of credit extended when deemed appropriate.
We maintain our cash and cash equivalent balances with high-quality financial institutions and consequently, we believe that such funds are subject to minimal credit risk.
Fair Value Measurements
Fair value is determined based on the assumptions that market participants would use in pricing the asset or liability. We utilize the following fair value hierarchy in determining fair values:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.
The carrying value of cash and cash equivalents, accounts receivable, accounts payable, and other accruals readily convertible into cash approximate fair value because of the short-term nature of the instruments. As further discussed in Note 2 - Acquisitions and Divestitures, we have classified the contingent consideration associated with the Valipat divestiture within Level 3 of the fair value hierarchy. As further discussed in Note 9 - Debt, we have classified our debt instruments within Level 2 of the fair value hierarchy. We have also classified our derivative instruments described in Note 8 - Derivative Instruments within Level 2 of the fair value hierarchy.
Cash and Cash Equivalents
Cash and cash equivalents is comprised of cash on hand and short-term deposits with an original maturity at the date of purchase of three months or less, and includes restricted cash of $10.5 and $12.9 as of December 31, 2024 and 2023, respectively.
Allowance for Credit Losses
We estimate credit losses for trade receivables by using a current expected credit loss model. The credit loss allowance is determined through an analysis of historical collection experience, the aging of accounts receivable, and an evaluation of the impact of current and projected economic conditions. Trade and other receivables are written off when there is no reasonable expectation of recovery, such as a past due status greater than 360 days or bankruptcy of the debtor.
Property and Equipment
Property and equipment is recorded at cost, and depreciation is recorded using the straight‑line method over the estimated useful lives of the assets, as follows:
Computer hardware3 years
Furniture, fixtures, and equipment
5 - 7 years
Leasehold improvementsLesser of lease term or estimated useful life
Repair and maintenance costs are expensed as incurred.
Internally Developed Software and Content
Internally Developed Software — Development costs related to internally generated software are capitalized once a project has progressed to the application development stage. Costs of significant improvements or enhancements on existing software for internal use, both internally developed and purchased, are also capitalized. Costs related to the preliminary project stage, data conversion, and post-implementation/operation stage of an internal-use software development project are expensed as incurred. Capitalized costs are amortized over five years, which is the estimated useful life of the related software. Purchased software is amortized over three years, which is the estimated useful life of the related software.
Content — Costs related to the acquisition of source materials, content selection, document processing, editing, abstracting, and indexing are capitalized. We also capitalize internal and external costs associated with the development of product-related software that adds functionality and improves the customer’s ability to search our content. These capitalized costs are amortized over a two to five year useful life.
We do not capitalize any costs associated with research and development or marketing.
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current portion of operating lease liability, and Operating lease liabilities on our Consolidated Balance Sheets. Our finance lease asset is included within Property and equipment, net on our Consolidated Balance Sheets (see Note 5 - Property and Equipment, Net) and the related finance lease liability is included as an item of indebtedness (see Note 9 - Debt) on our Consolidated Balance Sheets.
Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial valuation of finance lease assets and liabilities is calculated in the same way. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
We account for lease and non-lease components as a single lease component.
Goodwill and Other Intangible Assets
We account for our business combinations using the acquisition method of accounting. We allocate the purchase price of an acquisition to the assets acquired and liabilities assumed based on their estimated fair values. As part of this allocation process, we identify and attribute values and estimated lives to the intangible assets acquired. The excess of the purchase price over the fair values of identifiable assets and liabilities is recorded as goodwill.
Definite-lived intangible assets are generally amortized on a straight-line basis over the following estimated useful lives:
Customer relationships
2 - 23 years
Technology and content
2 - 20 years
Computer software5 years
Trade names and other
2 - 18 years
Goodwill and indefinite-lived intangible assets are not amortized, but instead are tested for impairment annually as of the first day of the fourth quarter, or more frequently if events or changes in circumstances indicate that the asset might be impaired.
Impairment of Long-Lived Assets
We evaluate our long-lived assets, including property and equipment, internally developed software and content, definite-lived intangible assets, and operating lease ROU assets for impairment whenever circumstances indicate the carrying value may not be recoverable. We determine the recoverability of a long-lived asset, or a group of similar long-lived assets, by comparing its carrying value to the future undiscounted cash flows that the asset is expected to generate over its remaining life. Any impairment is measured as the difference between the carrying value and the fair value of the asset.
Goodwill impairment testing is performed at the reporting unit level. For goodwill impairment testing purposes, we have determined that our business segments are our reporting units. As part of our annual goodwill impairment testing, we have the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If we bypass the qualitative assessment, or if the qualitative assessment indicates that quantitative analysis should be performed, we evaluate goodwill for impairment by comparing the estimated fair value of a reporting unit with its carrying amount, including goodwill. We estimate the fair value of a reporting unit using a discounted cash flow (“DCF”) analysis based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. We use our internal forecasts to estimate future cash flows and include an estimate of long-term future growth rates.
Our indefinite-lived intangible assets are related to trade names. Similar to goodwill, as part of our annual indefinite-lived intangible asset impairment testing, we have the option to first perform qualitative testing by evaluating whether any events and circumstances occurred that provide evidence that it is more likely than not that the indefinite-lived assets are impaired. If we do not believe that it is more likely than not that the indefinite-lived assets are impaired, no quantitative impairment test is required. If we choose not to complete a qualitative assessment, or if the qualitative assessment indicates that a quantitative analysis should be performed, we estimate the fair value of the indefinite-lived asset by using the relief-from-royalty method based on the present value of estimated future cash flows that the indefinite-lived asset is expected to generate in the future.
Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell.
Any impairment charge is recognized in full in the reporting period in which it has been identified. For discussion of the analysis and results of our impairment tests, see Note 6 - Other Intangible Assets, Net and Goodwill and Note 13 - Restructuring and Other Impairments.
Accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following:
December 31,
20242023
Liabilities due to customers$84.8 $62.0 
Accrued royalties79.3 75.4 
Miscellaneous accruals146.0 177.8 
Accrued expenses and other current liabilities$310.1 $315.2 
Income Taxes
We recognize income taxes under the asset and liability method. Deferred income tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred income tax assets and liabilities are recorded at the enacted tax rate expected to apply to the temporary difference when settled or realized. We record U.S. tax expense resulting from Global Intangible Low Taxed Income (“GILTI”) as a current period expense.
In assessing the realizability of deferred tax assets, we consider all available positive and negative evidence factors. Evidence considered includes historical and projected future taxable income by tax jurisdiction, character and timing of income or loss, and prudent and feasible tax planning strategies. We record a valuation allowance to reduce deferred tax assets to the net realizable value that is more likely than not to be realized.
We record tax benefits when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The amount of tax benefit recorded is the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement. We then record a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken on a tax return. Uncertain tax positions are reassessed quarterly and liabilities for unrecognized tax benefits are adjusted when our judgment changes as a result of the evaluation of new information, such as developments in case law, new regulations or tax law, or changes in the status of ongoing audits. These adjustments will be reflected as increases or decreases to income tax expense in the period in which new information is available. Accrued interest and penalties related to unrecognized tax benefits are included within the Provision (benefit) for income taxes in the Consolidated Statements of Operations.
Treasury Shares
Treasury share purchases, whether through share withholdings for taxes or repurchase programs and transactions, are recorded at cost. Issuances from treasury shares are recorded using the First In, First Out (“FIFO”) method.
Revenue Recognition
We derive revenue through subscriptions to our product offerings, re-occurring contracts in our IP segment, and transactional sales that are typically quoted on a product, data set, or project basis.
Subscription-based revenues are recurring revenues that we typically earn under annual contracts, pursuant to which we license the right to use our products to our customers or provide maintenance services over a contractual term. We invoice and collect the subscription fee at the beginning of the subscription period. For multi-year agreements, we generally invoice customers annually at the beginning of each annual coverage period. Cash received or receivable in advance of completing the performance obligations is included in deferred revenue. We recognize subscription revenue ratably over the contract term as the access or service is provided.
Re-occurring revenues are derived solely from the patent and trademark maintenance services provided by our IP segment. Patents and trademarks are renewed regularly, and our services help customers maintain and protect those patents and trademarks in multiple jurisdictions around the world. Because of the re-occurring nature of the patent and trademark lifecycle, our customer base engages us to manage the renewal process on their behalf. These contracts typically include evergreen clauses or are multi-year agreements. We invoice and recognize revenue upon delivery of the service.
Transactional revenues are earned for specific deliverables that are typically quoted on a product, data set, or project basis. Transactional revenues include content sales (including single-document and aggregated collection sales), consulting engagements, and other professional services such as software implementation services. We typically invoice and record revenue for this revenue stream upon delivery of the product, data set, or project, although for longer software implementation projects, we will periodically invoice and recognize revenue in connection with the completion of related performance obligations.
When multiple performance obligations exist in a single contract, the transaction price is allocated to each performance obligation in proportion to the standalone selling price of each performance obligation. The standalone selling price is typically determined by reference to our standard price lists and is a reflection of our normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. Discounts applied to the contract are allocated based on the same proportion of standalone selling prices.
For transactions that involve a third party, we evaluate whether we are acting as the principal or the agent in the transaction by considering factors such as control of the specified goods or services before they are transferred to the customer, fulfillment responsibility, collection risk, and discretion in establishing price. If we determine that we control the good or service before it is transferred to the customer, we recognize revenue on a gross basis. Conversely, if we determine that we do not control the good or service before it is transferred to the customer, we recognize revenue on a net basis.
We pay commissions to sales managers and support teams for earning new customers and renewing contracts with existing customers. We treat these commission costs as costs to obtain a contract and are therefore considered contract assets. We capitalize certain of these commission costs within Prepaid expenses and Other non-current assets on the Consolidated Balance Sheets. The costs are amortized to Selling, general and administrative costs within the Consolidated Statements of Operations. The amortization period is between one and seven years based on the estimated length of the customer relationship.
Share-based Compensation
We recognize compensation expense for share-based awards based on grant date fair value. The fair value of RSUs is based on the fair value of our common shares on the date of grant, and we use a Monte Carlo simulation to determine the fair value of our PSUs at grant date. We use the graded vesting method to amortize the value of share-based awards to expense. We recognize forfeitures as they occur.
Defined Contribution Plans
Employees participate in various defined contribution savings plans that provide for Company-matching contributions. Costs for future employee benefits are accrued over the periods in which employees earn the benefits. Total expense related to defined contribution plans was $37.3, $34.9, and $30.5 for the years ended December 31, 2024, 2023, and 2022, respectively, which approximates the cash outlays related to the plans.
Restructuring
Restructuring expense includes costs associated with involuntary termination benefits provided to employees, certain contract termination costs, and other costs associated with an exit or disposal activity. Involuntary termination benefits are recognized within restructuring charges at the time that the program was approved and all necessary communications were made. The liabilities are recorded within Accrued expenses and other current liabilities in the Consolidated Balance Sheets. The corresponding expenses are recorded within Restructuring and other impairments in the Consolidated Statements of Operations. For further details, see Note 13 - Restructuring and Other Impairments.
Legal Costs
Legal costs expected to be incurred in connection with a loss contingency are expensed and accrued at the outset of the legal matter giving rise to the estimated legal costs. We reassess the sufficiency of the accrual each reporting period.
Other Operating (Income) Expense, Net
Other operating expense (income), net consisted of the following:
Year Ended December 31,
202420232022
Gain on sale from divestitures
Note 2$(54.7)$— $(278.5)
Gain on legal settlement
Note 17— (49.4)— 
Net foreign exchange loss (gain)

4.2 38.9 (45.4)
Miscellaneous, net
(1.3)(0.3)(0.9)
Total$(51.8)$(10.8)$(324.8)
Foreign Currency Translation
The operations of each of our entities are measured using the currency of the primary economic environment in which the subsidiary operates (“functional currency”). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the accompanying Consolidated Balance Sheets.
Earnings Per Share
Basic earnings per share (“EPS”) is calculated by dividing net income (loss) attributable to ordinary shares by the weighted average number of ordinary shares outstanding for the applicable period. Diluted EPS is computed by dividing net income (loss) attributable to ordinary shares, adjusted for the change in fair value of the private placement warrants, by the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding for the applicable period. Diluted EPS reflects the potential dilution that could occur if securities were exercised or converted into ordinary shares, as calculated using the treasury stock method.
Recently Issued Accounting Standards
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is designed to provide greater income tax disclosure transparency by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in this update are effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently assessing the impact of this update on our related disclosures.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires footnote disclosure that disaggregates relevant expense captions, including the total amount of selling expenses. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027 on a prospective basis, with the option for retrospective application. Early adoption is permitted. We are currently assessing the impact of this update on our financial statement disclosures.
v3.25.0.1
Acquisitions and Divestitures
12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
Acquisitions and Divestitures Acquisitions and Divestitures
2024 Divestiture of ScholarOne
In the fourth quarter of 2024, in connection with focusing our efforts on our core A&G business assets, we sold our ScholarOne product group for net cash proceeds of $103.6. As a result of the divestiture, we recognized a gain of $69.5, which is included in Other operating expense (income), net in the Consolidated Statements of Operations.
2024 Divestiture of Valipat
During the second quarter of 2023, we agreed to sell a small product group within our IP segment, Valipat, for $33.8, payable in annual installments over ten years. As of December 31, 2024, the fair value of this contingent consideration receivable was $25.0, net of cash receipts, of which almost all is classified as Other non-current assets in the Consolidated Balance Sheets. We will remeasure this receivable on a recurring basis and record adjustments, as needed, based on the length of time remaining under the commercial agreement and changes in the amount to be realized each year based on actual financial results. Changes in fair value measurement of the contingent consideration is based on Level 3 inputs. The transaction closed in April 2024 and we recognized a loss of $14.8, which is included in Other operating expense (income), net in the Consolidated Statements of Operations.
Prior to the held-for-sale determination and accompanying impairment testing as of June 30, 2023, the carrying amount of the expected assets to be disposed of consisted almost entirely of purchase-related identifiable customer relationship intangible assets of $158.3. These intangible assets were reduced to estimated fair value of $26.1 based on the estimated present value of the consideration to be paid over ten years. The related impairment charge of $132.2 is included in Goodwill and intangible asset impairments in the Consolidated Statements of Operations for the year ended December 31, 2023.
2022 Divestiture of MarkMonitor Domain Management Business
In October 2022, we completed the sale of the MarkMonitor Domain Management business within our IP segment and we recognized a gain of $278.5, which is included in Other operating expense (income), net in the Consolidated Statement of Operations. The aggregate closing consideration primarily included proceeds, net of cash transferred of $285.0 and deferred closing consideration of $10.6 that was subsequently received during the year ended December 31, 2023
v3.25.0.1
Revenue
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
We disaggregate our revenues by transaction type, by segment (see Note 16 - Segment Information), and by geography.
The following tables present our revenues by transaction type, based on revenue recognition pattern, and by geography, based on the location of the customer:
Year Ended December 31,
Revenues by transaction type 202420232022
Subscription revenues$1,626.8 $1,618.1 $1,618.8 
Re-occurring revenues429.8 444.6 441.9 
Transactional revenues
500.1 566.1 599.1 
Revenues$2,556.7 $2,628.8 $2,659.8 
Year Ended December 31,
Revenues by geography202420232022
Americas$1,381.4 $1,405.5 $1,462.3 
Europe/Middle East/Africa667.8 707.5 698.3 
APAC507.5 515.8 499.2 
Revenues$2,556.7 $2,628.8 $2,659.8 
For the year ended December 31, 2024, 2023, and 2022, approximately 50%, 49%, and 50% of our revenues, respectively, were attributed to customers in the U.S., while no other country accounted for more than 10% of our revenues.
As of December 31, 2024 and 2023, the capitalized amount of sales commissions included in Prepaid expenses was $15.4 and $19.7, respectively, and the capitalized amount included in Other non-current assets was $21.4 and $23.8, respectively. We have not recorded any impairments against these capitalized commission costs.
The following table presents our contract balances:
December 31,
20242023
Accounts receivable, net$798.3 $908.3 
Current portion of deferred revenues$859.1 $983.1 
Non-current portion of deferred revenues$16.6 $38.7 
During the year ended December 31, 2024, we recognized revenues of $868.2 attributable to deferred revenues recorded at the beginning of the period, primarily consisting of subscription revenues recognized ratably over the contractual term.
Our remaining performance obligations are included in the current or non-current portion of deferred revenues on the Consolidated Balance Sheets. The majority of these obligations relate to customer contracts where we license the right to use our products or provide maintenance services over a contractual term, generally one year or less.
v3.25.0.1
Accounts Receivable
12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Accounts Receivable Accounts Receivable
Our Accounts receivable, net balance consisted of the following:
December 31,
20242023
Accounts receivable$814.5 $934.9 
Less: Accounts receivable allowance(16.2)(26.6)
Accounts receivable, net$798.3 $908.3 
The change in our accounts receivable allowance related to the following activity during each of the years presented:
Year Ended December 31,
202420232022
Balance at beginning of year$26.6 $27.1 $24.9 
Additional provisions3.2 7.0 10.9 
Write-offs(12.9)(9.3)(7.8)
Exchange differences(0.7)1.8 (0.9)
Balance at end of year
$16.2 $26.6 $27.1 
v3.25.0.1
Property and Equipment, Net
12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Property and Equipment, Net Property and Equipment, Net
Property and equipment, net consisted of the following:
December 31,
20242023
Computer hardware$64.3 $54.5 
Leasehold improvements21.6 15.9 
Furniture, fixtures, and equipment
46.6 44.5 
Finance lease
8.0 8.0 
Other2.2 2.3 
Property and equipment, gross$142.7 $125.2 
Accumulated depreciation(89.2)(73.6)
Property and equipment, net$53.5 $51.6 
Depreciation expense was $19.0, $23.2, and $35.2 for the years ended December 31, 2024, 2023 and 2022, respectively.
v3.25.0.1
Other Intangible Assets, Net and Goodwill
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangible Assets, Net and Goodwill Other Intangible Assets, Net and Goodwill
Other intangible assets, net
The following tables summarize the gross carrying amounts and accumulated amortization of our identifiable intangible assets by major class:
December 31, 2024December 31, 2023
GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite-lived intangible assets:
Customer relationships$7,773.9 $(1,515.9)$6,258.0 $7,819.9 $(1,177.2)$6,642.7 
Technology and content2,748.8 (1,204.6)1,544.2 2,798.3 (1,009.1)1,789.2 
Computer software1,060.6 (609.2)451.4 897.9 (516.4)381.5 
Trade names and other
88.4 (57.7)30.7 88.9 (52.6)36.3 
Definite-lived intangible assets
$11,671.7 $(3,387.4)$8,284.3 $11,605.0 $(2,755.3)$8,849.7 
Indefinite-lived intangible assets:
Trade names156.9 — 156.9 156.9 — 156.9 
Total intangible assets$11,828.6 $(3,387.4)$8,441.2 $11,761.9 $(2,755.3)$9,006.6 
Intangible assets amortization expense was $708.0, $685.1, and $675.3 during the years ended December 31, 2024, 2023, and 2022, respectively.
In December 2024, our Board approved the wind-down of three product groups within the LS&H and A&G segments in connection with the Value Creation Plan and we recorded an intangible assets impairment charge of $75.0 to write down the carrying values of the associated intangibles, primarily technology and content assets, to their respective estimated net book values.
In connection with the Valipat divestiture and related assets and liabilities held-for-sale as of December 31, 2023 (see Note 2 - Acquisitions and Divestitures for further details), we recorded an intangible assets impairment charge of $132.2 during the year ended December 31, 2023, primarily associated with purchase-related customer relationships.
As of December 31, 2024, the remaining weighted-average estimated useful life (in years) of our definite-lived intangible assets, by major class and in total, was as follows:
Customer relationships18
Technology and content9
Computer software6
Trade names and other
7
Total16
As of December 31, 2024, estimated future amortization expense related to definite-lived intangible assets was as follows:
2025$680.2 
2026646.9 
2027612.9 
2028581.3 
2029538.1 
Thereafter5,209.1 
Amortizing intangible assets
$8,268.5 
Internally developed software projects in process15.8 
Definite-lived intangible assets
$8,284.3 
Goodwill
The change in the carrying amount of Goodwill by segment was as follows:
A&G
Segment
IP
Segment
LS&H
Segment
Total
Consolidated
Balance as of December 31, 2022$1,109.8 $590.3 $1,176.4 $2,876.5 
Acquisition
— — 3.0 3.0 
Goodwill impairment
— (582.2)(265.5)(847.7)
Impact of foreign currency fluctuations
— (8.1)— (8.1)
Balance as of December 31, 2023$1,109.8 $— $913.9 $2,023.7 
Acquisition— 13.8 15.8 29.6 
Goodwill impairment
— (13.8)(451.9)(465.7)
Divestiture(1)
(20.6)— — (20.6)
Impact of foreign currency fluctuations
(0.4)— — (0.4)
Balance as of December 31, 2024$1,088.8 $— $477.8 $1,566.6 
(1) Related to the ScholarOne divestiture and its allocated portion of the A&G segment reporting unit’s goodwill balance. For further details, see Note 2 - Acquisitions and Divestitures.
In both 2024 and 2023, we completed quantitative goodwill impairment assessments using a DCF analysis to estimate the fair value of each of our reporting units. For additional information related to our goodwill impairment testing policy and procedures, see Note 1 - Nature of Operations and Summary of Significant Accounting Policies.
In the fourth quarter of 2023, we performed our annual goodwill impairment assessment and determined that the carrying value of the IP and LS&H segment reporting units exceeded their respective fair values, resulting in a goodwill impairment charge of $844.7 as follows: (i) $579.2 related to the IP reporting unit within the IP segment and (ii) $265.5 related to the LS&H reporting unit within the LS&H segment. The impairments were primarily due to worsening macroeconomic and market conditions. Separate from the annual quantitative goodwill impairment assessment, in connection with the Valipat divestiture (see Note 2 - Acquisitions and Divestitures for further details), we recorded a $3.0 goodwill impairment related to its allocated portion of the IP segment reporting unit’s goodwill balance.
In the second quarter of 2024, primarily due to sustained declines in our share price, we determined that it was appropriate to perform an interim quantitative goodwill impairment assessment and concluded that the estimated fair value of the A&G reporting unit was substantially in excess of its carrying value. For the LS&H reporting unit, we determined the carrying value exceeded its fair value; consequently, we recorded a goodwill impairment charge of $302.8.
In the third quarter of 2024, we recorded $13.8 of goodwill associated with a small acquisition within the IP reporting unit. We recorded an impairment to the goodwill because the IP reporting unit’s fair value was significantly below its carrying value based on the results of our second quarter 2024 interim quantitative impairment assessment.
In the fourth quarter of 2024, we performed our annual goodwill impairment assessment and, while the estimated fair value decreased for all reporting units, we concluded that the estimated fair value of the A&G reporting unit continued to be substantially in excess of its carrying value. For the LS&H reporting unit, we determined the carrying value exceeded its fair value; consequently, we recorded a goodwill impairment charge of $149.1. The impairment was primarily due to sustained declines in our share price.
v3.25.0.1
Leases
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Leases Leases
We currently lease office space and certain equipment under non-cancelable operating lease agreements. We also have one financing lease for office space. Some of our leases include renewal options, which we do not consider with respect to the lease term used for calculating the lease liability because the renewal options allow us to maintain operational flexibility, and we are not reasonably certain we will exercise the renewal options.
The following table presents the components of our lease cost, supplemental cash flow disclosures, and other information related to our lease arrangements:
Year Ended December 31,
202420232022
Lease Cost:
Operating lease cost$20.2 $22.4 $27.9 
Variable lease cost4.0 5.3 2.5 
Short-term lease cost0.8 0.7 0.4 
Finance lease cost:
     Amortization
0.3 0.5 10.8 
     Interest
2.1 2.1 1.2 
Total lease cost$27.4 $31.0 $42.8 
Supplemental Cash Flow Disclosures:
Cash paid for amounts included in measurement of lease liabilities
Operating cash flows for operating leases$30.3$31.9$34.7
Operating cash flows for finance leases2.12.11.2
Financing cash flows for finance leases1.21.01.9
Right-of-use assets obtained in exchange for lease obligations
Operating leases$16.8$16.2$2.6
Finance leases2.4
Other Information:
Weighted-average remaining lease term
Operating leases555
Finance leases121314
Weighted-average discount rate
Operating leases6.2 %5.2 %4.3 %
Finance leases6.9 %6.9 %6.9 %
The following table presents an analysis of our lease liability maturities as of December 31, 2024:
Year Ending December 31,
Operating LeasesFinance Leases
2025$24.4 $3.3 
202618.6 3.4 
202713.7 3.4 
20288.0 3.5 
20296.7 3.6 
Thereafter15.3 26.3 
Total undiscounted cash flows $86.7 $43.5 
Present value:
Current lease liabilities20.6 1.3 
Non-current lease liabilities53.2 28.0 
Total lease liabilities$73.8 $29.3 
Interest on lease liabilities$12.9 $14.2 
Leases Leases
We currently lease office space and certain equipment under non-cancelable operating lease agreements. We also have one financing lease for office space. Some of our leases include renewal options, which we do not consider with respect to the lease term used for calculating the lease liability because the renewal options allow us to maintain operational flexibility, and we are not reasonably certain we will exercise the renewal options.
The following table presents the components of our lease cost, supplemental cash flow disclosures, and other information related to our lease arrangements:
Year Ended December 31,
202420232022
Lease Cost:
Operating lease cost$20.2 $22.4 $27.9 
Variable lease cost4.0 5.3 2.5 
Short-term lease cost0.8 0.7 0.4 
Finance lease cost:
     Amortization
0.3 0.5 10.8 
     Interest
2.1 2.1 1.2 
Total lease cost$27.4 $31.0 $42.8 
Supplemental Cash Flow Disclosures:
Cash paid for amounts included in measurement of lease liabilities
Operating cash flows for operating leases$30.3$31.9$34.7
Operating cash flows for finance leases2.12.11.2
Financing cash flows for finance leases1.21.01.9
Right-of-use assets obtained in exchange for lease obligations
Operating leases$16.8$16.2$2.6
Finance leases2.4
Other Information:
Weighted-average remaining lease term
Operating leases555
Finance leases121314
Weighted-average discount rate
Operating leases6.2 %5.2 %4.3 %
Finance leases6.9 %6.9 %6.9 %
The following table presents an analysis of our lease liability maturities as of December 31, 2024:
Year Ending December 31,
Operating LeasesFinance Leases
2025$24.4 $3.3 
202618.6 3.4 
202713.7 3.4 
20288.0 3.5 
20296.7 3.6 
Thereafter15.3 26.3 
Total undiscounted cash flows $86.7 $43.5 
Present value:
Current lease liabilities20.6 1.3 
Non-current lease liabilities53.2 28.0 
Total lease liabilities$73.8 $29.3 
Interest on lease liabilities$12.9 $14.2 
v3.25.0.1
Derivative Instruments
12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Instruments Derivative Instruments
We are exposed to various market risks, including foreign currency exchange rate risk and interest rate risk. We use derivative instruments to manage these risk exposures. We enter into foreign currency contracts and cross-currency swaps to help manage our exposure to foreign currency exchange rate risk, and we use interest rate swaps to mitigate interest rate risk.
Interest Rate Swaps
We have interest rate swap arrangements with counterparties to reduce our exposure to variability in cash flows relating to interest payments on our outstanding term loan arrangements. We have designated the interest rate swaps as cash flow hedges of the risk associated with floating interest rates on designated future monthly interest payments. For additional information on our outstanding term loan facility, see Note 9 - Debt. As of December 31, 2024, our outstanding interest rate swaps have an aggregate notional value of $750.8 and mature in October 2026.
The fair value of the interest rate swaps is the estimated amount that we would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Changes in fair value are recorded in Accumulated other comprehensive loss (“AOCL”) in the Consolidated Balance Sheets with a related offset in derivative asset or liability, and the amounts reclassified out of AOCL are recorded in Interest expense, net in the Consolidated Statements of Operations. Any gain or loss will be subsequently reclassified into net earnings in the same period during which transactions affect earnings, or upon termination of the arrangements. For additional information on changes recorded to AOCL, see Note 10 - Shareholders' Equity. As of December 31, 2024, we estimate that approximately $8.8 of pre-tax gain related to interest rate swaps recorded in AOCL will be reclassified into earnings within the next 12 months.
Cross-Currency Swaps
In July 2023, we entered into a cross-currency swap that matures in 2026 to mitigate foreign currency exposure related to our net investment in various euro-functional-currency consolidated subsidiaries. This swap is designated and qualifies as a net investment hedge. We elected to assess the effectiveness of this net investment hedge based on changes in spot rates and are amortizing the portion of the net investment hedge that was excluded from the assessment of effectiveness over the life of the swap within Interest expense, net in the Consolidated Statements of Operations. The notional amount of the cross-currency swap associated with euro-denominated subsidiary net investments was €100.0 as of December 31, 2024.
Changes in fair value are recorded in AOCL (as a foreign currency translation adjustment) in the Consolidated Balance Sheets, with a related offset in derivative asset or liability. Any gain or loss will be subsequently reclassified into net earnings when the hedged net investment is either sold or substantially liquidated. For additional information on changes recorded to AOCL, see Note 10 - Shareholders' Equity.
Foreign Currency Forward Contracts
We periodically enter into foreign currency contracts, which generally do not exceed 180 days in duration, to help manage our exposure to foreign exchange rate risks. We have not designated these contracts as accounting hedges.
We initially recognize these contracts at fair value on the execution date and subsequently remeasure the contracts to their fair value at the end of each reporting period. We assess the fair value of these instruments by considering current and anticipated movements in future interest rates and the relevant currency spot and future rates available in the market. We receive third-party valuation reports to corroborate our determination of fair value.
We recognize the associated realized and unrealized gains and losses in Other operating expense (income), net in the Consolidated Statements of Operations. We recognized a loss (gain) from the fair value adjustment of $2.3, $(0.8), and $1.2, for the years ended December 31, 2024, 2023, and 2022, respectively. The notional amount of outstanding foreign currency contracts was $91.1 and $140.5 as of December 31, 2024 and December 31, 2023, respectively.
The following table provides information on the location and fair value amounts of our derivative instruments:
December 31,
Balance Sheet Classification20242023
Asset Derivatives
Designated as accounting hedges:
Interest rate swapsOther current assets$— $4.1 
Interest rate swapsOther non-current assets14.7 17.7 
Cross-currency swaps
Other non-current assets3.7 — 
Not designated as accounting hedges:
Foreign currency forwardsOther current assets— 1.3 
Total Asset Derivatives$18.4 $23.1 
Liability Derivatives
Designated as accounting hedges:
Cross-currency swaps
Other non-current liabilities$— $2.0 
Not designated as accounting hedges:
Foreign currency forwardsAccrued expenses and other current liabilities1.1 0.1 
Total Liability Derivatives$1.1 $2.1 
v3.25.0.1
Debt
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Debt Debt
The following table summarizes our total indebtedness:
December 31, 2024December 31, 2023
TypeMaturityEffective
Interest
Rate
Carrying
Value
Effective
Interest
Rate
Carrying
Value
Senior Notes20294.875%$921.4 4.875 %$921.4 
Senior Secured Notes20283.875%921.2 3.875 %921.2 
Senior Secured Notes20264.500%700.0 4.500 %700.0 
Revolving Credit Facility20297.107%— 8.206 %— 
Term Loan Facility 20317.107%1,999.2 8.470 %2,197.4 
Finance lease
20366.936%29.3 6.936 %30.3 
Total debt outstanding$4,571.1 $4,770.3 
Debt discounts and issuance costs(51.1)(48.0)
Current portion of long-term debt(1.3)(1.2)
Long-term debt$4,518.7 $4,721.1 
Senior Notes (2029) and Senior Secured Notes (2028)
Interest on the Senior Notes due 2029 and Senior Secured Notes due 2028 is payable semi-annually to holders of record on June 30 and December 30 of each year. The Senior Secured Notes due 2028 are secured on a first-lien pari passu basis with borrowings under our credit facilities and Senior Secured Notes due 2026. Both series of Notes are guaranteed on a joint and several basis by each of our indirect subsidiaries that is an obligor or guarantor under our credit facilities and Senior Secured Notes due 2026.
The Senior Notes due 2029 and Senior Secured Notes due 2028 are subject to redemption as a result of certain changes in control at 101% of the principal amount, plus accrued and unpaid interest to the date of purchase. Additionally, at our election, both series of Notes may be redeemed during the 12 month period commencing on June 30 of each of the years referenced below based on the call premiums listed below, plus accrued and unpaid interest to the date of redemption.
Redemption Price
(as a percentage of principal)
PeriodSenior Notes (2029)Senior Secured Notes (2028)
2024102.438 %101.938 %
2025101.219 %100.969 %
2026 and thereafter100.000 %100.000 %
The indentures governing these Notes contain covenants which, among other things, limit the incurrence of additional indebtedness (including acquired indebtedness), issuance of certain preferred stock, the payment of dividends, making restricted payments and investments, the purchase or acquisition or retirement for value of any equity interests, the provision of loans or advances to restricted subsidiaries, the sale or lease or transfer of any properties to any restricted subsidiaries, the transfer or sale of assets, and the creation of certain liens. As of December 31, 2024, we were in compliance with all of the indenture covenants.
Senior Secured Notes (2026)
Interest on the Senior Secured Notes due 2026 is payable semi-annually to holders of record on May 1 and November 1 of each year. The Senior Secured Notes due 2026 are secured on a first-lien pari passu basis with borrowings under our credit facilities and Senior Secured Notes due 2028. These Notes are guaranteed on a joint and several basis by each of our indirect subsidiaries that is an obligor or guarantor under our credit facilities and are secured on a first-priority basis by the collateral now owned or hereafter acquired by Camelot Finance S.A. (the issuer) and each of the guarantors that secures the issuer’s and such guarantor’s obligations under our credit facilities (subject to permitted liens and other exceptions).
The Senior Secured Notes due 2026 are subject to redemption as a result of certain changes in tax laws or treaties of (or their interpretation by) a relevant tax jurisdiction at 100% of the principal amount, plus accrued and unpaid interest to the date of redemption, and upon certain changes in control at 101% of the principal amount, plus accrued and unpaid interest to the date of purchase. Additionally, at our election, the Notes may be redeemed at 100% of the principal amount, plus accrued and unpaid interest to the date of redemption.
The Credit Facilities
In January 2024, we refinanced our existing Term Loan Facility and extended the maturity date of our Revolving Credit Facility, which together are our Credit Facilities, as further described below. The strategic refinancing provides improved financial flexibility, including extending our debt maturities and lowering our annual cash interest costs.
Borrowings under the Credit Facilities bear interest at a floating rate equal to (i) Term SOFR (as defined in the Credit Agreement) for the interest period elected by us plus 2.75% per annum, in the case of Term SOFR loans, and (ii) an alternate base rate (“ABR”), equal to the highest of (a) the Federal Funds Rate plus one-half of 1.0%, (b) the Prime Rate, and (c) Term SOFR with an interest period of one month plus 1.0%, plus 1.75% per annum, in the case of ABR loans.
The Credit Facilities are secured by substantially all of our assets and the assets of all of our U.S. restricted subsidiaries and certain of our non-U.S. subsidiaries, including those that are or may be borrowers or guarantors under the Credit Facilities, subject to customary exceptions. The Credit Agreement governing the Credit Facilities contains customary events of default and restrictive covenants that limit us from, among other things, incurring certain additional indebtedness, issuing preferred stock, making certain restricted payments and investments, certain transfers or sales of assets, entering into certain affiliate transactions, or incurring certain liens.
The Credit Facilities provide that, upon the occurrence of certain events of default, our obligations thereunder may be accelerated and the lending commitments terminated. Such events of default include payment defaults to the lenders, material inaccuracies of representations and warranties, covenant defaults, cross-defaults to other material indebtedness (including the Senior Secured Notes due 2026, the Senior Secured Notes due 2028, and the Senior Notes due 2029), voluntary and involuntary bankruptcy proceedings, material money judgments, loss of perfection over a material portion of collateral, material ERISA/pension plan events, certain change of control events, and other customary events of default, in each case subject to threshold, notice, and grace period provisions.
We may be subject to certain negative covenants, including either a fixed charge coverage ratio, total first lien net leverage ratio, or total net leverage ratio if certain conditions are met. As of December 31, 2024, we were in compliance with the covenants for the credit facilities.
Revolving Credit Facility (2029)
Our revolving credit facility provides for revolving loans, same-day borrowings, and letters of credit. Proceeds of loans made under the revolving credit facility may be borrowed, repaid, and reborrowed prior to maturity.
In the January 2024 refinancing, we reduced our revolving credit facility from $750.0 to $700.0 (with a letter of credit sublimit of $77.0) and extended the maturity date from March 31, 2027 to January 31, 2029, subject to a “springing” maturity date that is 91 days prior to the maturity date of the Senior Secured Notes due 2026 and the Senior Secured Notes due 2028, but only to the extent that those notes have not been refinanced or extended prior to their original maturity dates. All other terms related to the revolving credit facility were substantively unchanged.
The Revolving Credit Facility carries a base interest rate at Term SOFR, plus 3.25% per annum (or 2.75% per annum, based on first lien leverage ratios) or Prime plus a margin of 2.25% per annum, as applicable depending on the borrowing. The Revolving Credit Facility interest rate margins will decrease upon the achievement of certain first lien net leverage ratios (as the term is used in the Credit Agreement) and is subject to a commitment fee rate of 0.5% per annum (or 0.375% per annum, based on first lien leverage ratios) times the unutilized amount of total revolving commitments.
As of December 31, 2024, letters of credit totaling $7.7 were collateralized by the revolving credit facility.
Term Loan Facility (2031)
In the January 2024 refinancing, we made a prepayment of $47.4 on the existing term loans due in 2026 and then refinanced the remaining term loans with a new $2,150.0 tranche of term loans maturing in 2031. The interest rate margin for the new term loan facility decreased from 300 to 275 basis points per annum in the case of loans bearing interest by reference to Term SOFR. The term loans amortize in equal quarterly installments (the first installment was paid on June 28, 2024) equivalent to a rate of 1.00% per annum, with the balance due at maturity. Any optional prepayments are applied against the scheduled quarterly installments of principal in the direct order of maturity. We paid the first and second quarterly installments and, during the fourth quarter of 2024, made prepayments of $140.0.
The carrying value of our variable interest rate debt, excluding unamortized debt issuance costs, approximates fair value due to the short-term nature of the interest rate benchmark rates. The fair value of the fixed rate debt is estimated based on market observable data for debt with similar prepayment features. The fair value of our debt was $4,423.2 and $4,615.3 at December 31, 2024 and December 31, 2023, respectively, and is considered Level 2 under the fair value hierarchy.
Amounts due under our outstanding borrowings as of December 31, 2024 are as follows:
2025$1.3 
2026701.5 
20271.7 
2028923.1 
2029
923.5 
Thereafter2,020.0 
Total maturities$4,571.1 
Less: capitalized debt issuance costs and original issue discount(51.1)
Total, including the current portion of long-term debt$4,520.0 
v3.25.0.1
Shareholders' Equity
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Shareholders' Equity Shareholders' Equity
Conversion of Preferred Shares into Ordinary Shares
On June 3, 2024, all 14.4 million outstanding shares of our 5.25% Series A Mandatory Convertible Preferred Shares (“MCPS”) automatically converted into 55.3 million ordinary shares at a conversion rate of 3.8462 ordinary shares per MCPS share. All accumulated preferred dividends were paid prior to the conversion.
Share Repurchase Program
In February 2022, our Board of Directors approved the purchase of up to $1,000.0 of our ordinary shares through open-market purchases, to be executed through December 31, 2023. During the year ended December 31, 2022, we repurchased approximately 10.7 million ordinary shares for $175.0 at an average price of $16.33 per share. All repurchased shares were subsequently retired at an average price of $15.61 per share and were restored as authorized but unissued ordinary shares. In accordance with ASC Topic 505, Equity, we reduced our ordinary shares account by the carrying amount at the time of formal retirement and, due to the difference from the original repurchase share value, an associated loss of $(7.7) was recognized in the Consolidated Statement of Changes in Equity.
In May 2023, our Board of Directors approved the extension of the share repurchase authorization, but reduced the authorization from $1,000.0 to $500.0. During the year ended December 31, 2023, we repurchased approximately 13.8 million ordinary shares for $100.0 at an average price of $7.22 per share and, during the year ended December 31, 2024, we repurchased approximately 34.4 million ordinary shares for $200.0 at an average price of $5.81 per share. All repurchased shares were immediately retired and restored as authorized but unissued ordinary shares. The authorization for this share repurchase program terminated on December 31, 2024.
In December 2024, our Board authorized a new share repurchase program of up to $500.0 of our ordinary shares for a period of two years, from January 1, 2025 through December 31, 2026.
Accumulated Other Comprehensive Income (Loss) (“AOCI” or “AOCL”)
The table below provides information about the changes in Accumulated Other Comprehensive Income (Loss) by component and the related amounts reclassified to net earnings during the periods indicated (net of tax). The foreign currency translation adjustment component of AOCL represents the impact of translating foreign subsidiary asset and liability balances from their local currency to USD. The change in each period below was primarily related to foreign subsidiaries whose local currency is GBP.
Interest rate swapsDefined benefit pension plansForeign currency translation adjustmentAccumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2021
$1.1 $(1.4)$327.0 $326.7 
Other comprehensive income (loss) before reclassifications41.1 2.9 (1,032.5)(988.5)
Reclassifications from AOCL to net earnings(4.1)— — (4.1)
Net other comprehensive income (loss)
37.0 2.9 (1,032.5)(992.6)
Balance as of December 31, 2022$38.1 $1.5 $(705.5)$(665.9)
Other comprehensive income (loss) before reclassifications14.9 (1.1)194.2 208.0 
Reclassifications from AOCL to net earnings(36.8)— (0.6)(37.4)
Net other comprehensive income (loss)
(21.9)(1.1)193.6 170.6 
Balance as of December 31, 2023$16.2 $0.4 $(511.9)$(495.3)
Other comprehensive income (loss) before reclassifications16.1 (0.8)(40.4)(25.1)
Reclassifications from AOCL to net earnings(21.6)— 15.7 (5.9)
Net other comprehensive income (loss)
(5.5)(0.8)(24.7)(31.0)
Balance as of December 31, 2024$10.7 $(0.4)$(536.6)$(526.3)
CPA Global Acquisition Shares
During the year ended December 31, 2022, the Employee Benefit Trust (“EBT”), established for the CPA Global Equity Plan, was terminated after the last remaining 0.5 million treasury shares held in the EBT were sold at an average price of $10.72 per share. Due to the difference from the original value of $30.99 per share as of the CPA Global acquisition date in October 2020, an associated loss of $(11.2) was recognized in the Consolidated Statement of Changes in Equity.
v3.25.0.1
Private Placement Warrants
12 Months Ended
Dec. 31, 2024
Other Liabilities Disclosure [Abstract]  
Private Placement Warrants Private Placement Warrants
In May 2024, the remaining 17.8 million private placement warrants expired unexercised. These warrants had an exercise price of $11.50 per share and were valued using a Black-Scholes option valuation model and classified as Level 3 financial instruments within the fair value hierarchy. The warrants were subject to remeasurement at each balance sheet date and represented a liability balance of zero and $5.1 as of December 31, 2024 and December 31, 2023, respectively, classified within Accrued expenses and other current liabilities in the Consolidated Balance Sheets. The change in fair value was recognized as a fair value adjustment of warrants in the Consolidated Statements of Operations.
v3.25.0.1
Share-based Compensation
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based Compensation Share-based Compensation
We grant share-based awards under the Clarivate Plc 2019 Incentive Award Plan (“the Plan”). A maximum aggregate amount of 60.0 million ordinary shares are reserved for issuance under the Plan. The Plan provides for the issuance of options, share appreciation rights, restricted shares, restricted share units, and cash awards. As of December 31, 2024 and 2023, approximately 20.7 million and 26.8 million shares, respectively, of our ordinary shares were available for share-based awards.
Total share-based compensation expense for the years ended December 31, 2024, 2023, and 2022, comprised the following:
Year Ended December 31,
202420232022
Cost of revenues$14.6 $39.9 $36.3 
Selling, general and administrative costs46.0 69.0 65.9 
Total share-based compensation expense$60.6 $108.9 $102.2 
Total income tax provision (benefit) recognized for stock-based compensation arrangements were as follows:
Year Ended December 31,
202420232022
Provision (benefit) for income taxes$(2.2)$(8.7)$(8.3)
Restricted Share Units (“RSUs”) and Performance Share Units (“PSUs”)
RSUs typically vest from one to three years under a graded vesting method. RSUs do not have nonforfeitable rights to dividends or dividend equivalents. The fair value of RSUs is based on the fair value of our common shares on the date of grant.
PSUs typically either cliff vest over three years or vest ratably between three and five years. Payout percentages are based on accomplishing certain levels of growth and profitability, subsequently adjusted for our total shareholder return (“TSR”) compared to the TSR of the S&P 500. We use a Monte Carlo simulation to determine the fair value of our PSUs at grant date. Each quarter, we evaluate the likelihood that the performance criteria will be met. As the number of PSUs expected to vest increases or decreases, compensation expense is also adjusted up or down to reflect the number of shares expected to vest and the cumulative vesting period met to date.
A summary of RSU and PSU activity for the year ended December 31, 2024, is presented below:
Year Ended December 31, 2024
RSUsRSUs Weighted
Average Grant Date Fair Value
PSUsPSUs Weighted
Average Grant Date Fair Value
Outstanding at December 31, 202310.8 $11.89 2.8 $12.95 
Granted9.1 6.892.6 7.77
Vested
(6.6)12.10(0.3)15.15
Forfeited
(1.0)9.55(1.1)9.10
Outstanding at December 31, 202412.3 $8.27 4.0 $10.48 
Total remaining unamortized compensation costs$38.0 $11.4 
Weighted average remaining service period0.91 years1.58 years
The 2024, 2023, and 2022 weighted average grant date fair value for RSUs was $6.89, $10.34, and $12.14 and for PSUs was $7.77, $13.55, and $13.83, respectively.
For the years ended December 31, 2024, 2023, and 2022, the fair value of RSUs vested was $45.3, $62.4, and $39.9, respectively, and the fair value of PSUs vested was insignificant.
Stock Options
No stock option awards have been granted to plan participants since 2019. Outstanding options were granted to plan participants at a price equal to the market price on the grant date, and their fair value was determined using a Black-Scholes model. As of December 31, 2024 and 2023, there was no unrecognized compensation cost related to outstanding stock options. As of December 31, 2024, we have 1.9 million options vested and exercisable at a weighted average exercise price per share of $12.60 with a weighted-average remaining contractual life of 3.4 years.
v3.25.0.1
Restructuring and Other Impairments
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Other Impairments Restructuring and Other Impairments
We have engaged in various restructuring programs to strengthen our business and streamline our operations, including taking actions related to the location and use of leased facilities. Our recent restructuring programs include the following:
Value Creation Plan - During the fourth quarter of 2024, we approved a broad-based plan to optimize our business model, which includes a cost rationalization component. We expect to incur approximately $30 of additional restructuring costs, primarily from a reduction in workforce, a majority of which we expect to incur in 2025.
Segment Optimization - During the second quarter of 2023, we approved a restructuring plan to reduce operational costs within targeted areas of the Company, with the primary cost savings driver being from a reduction in workforce. This program is now substantially complete.
ProQuest Acquisition Integration - During the fourth quarter of 2021, we approved a restructuring plan to reduce operational costs within targeted areas of the Company, with the primary cost savings driver being from a reduction in workforce. This program is complete.
One Clarivate and other restructuring programs - During the second quarter of 2021, we approved a restructuring plan to reduce operational costs within targeted areas of the Company, with the primary cost savings driver being from a reduction in workforce. These programs are complete.
The following table summarizes the pre-tax charges by activity and program during the periods indicated:
Year Ended December 31,
202420232022
Severance and related benefit costs:
Value Creation Plan
$0.5 $— $— 
Segment Optimization
19.9 13.4 — 
ProQuest Acquisition Integration
(0.1)16.7 22.9 
One Clarivate and other restructuring programs
— — 16.3 
Total Severance and related benefit costs
20.3 30.1 39.2 
Exit and disposal costs:
Value Creation Plan
0.1 — — 
Segment Optimization Program0.3 — — 
ProQuest Acquisition Integration
— 0.2 2.2 
One Clarivate and other restructuring programs
— — 1.0 
Total Exit and disposal costs
0.4 0.2 3.2 
Lease abandonment costs:
Value Creation Plan
— — — 
Segment Optimization
(1.1)3.7 — 
ProQuest Acquisition Integration
— — 24.3 
One Clarivate and other restructuring programs
— (0.1)— 
Total Lease abandonment costs
(1.1)3.6 24.3 
Restructuring costs
$19.6 $33.9 $66.7 
The following table summarizes the pre-tax charges by program and segment during the periods indicated:
Year Ended December 31,
202420232022
Academia & Government:
Value Creation Plan
$0.1 $— $— 
Segment Optimization7.0 4.8 — 
ProQuest Acquisition Integration
(0.1)9.1 26.5 
One Clarivate and other restructuring programs
— (0.1)9.7 
Total A&G
7.0 13.8 36.2 
Intellectual Property:
Value Creation Plan
0.5 — — 
Segment Optimization5.3 4.6 — 
ProQuest Acquisition Integration
— 4.6 15.3 
One Clarivate and other restructuring programs
— — 4.6 
Total IP
5.8 9.2 19.9 
Life Sciences & Healthcare:
Segment Optimization6.8 7.7 — 
ProQuest Acquisition Integration
— 3.2 7.6 
One Clarivate and other restructuring programs
— — 3.0 
Total LS&H
6.8 10.9 10.6 
Restructuring costs
$19.6 $33.9 $66.7 
The table below summarizes the changes in our restructuring reserves by activity during the periods indicated:
Severance and related benefit costs
Exit, disposal, and abandonment costs
Total
Reserve balance as of December 31, 2022$11.5 $0.1 $11.6 
Expenses recorded30.1 3.8 33.9 
Payments made(29.9)(2.5)(32.4)
Noncash items(5.8)— (5.8)
Reserve balance as of December 31, 2023$5.9 $1.4 $7.3 
Expenses recorded20.3 (0.7)19.6 
Payments made(22.4)(4.8)(27.2)
Noncash items(1.5)4.1 2.6 
Reserve balance as of December 31, 2024$2.3 $— $2.3 
Other impairments
In the fourth quarter of 2023, we recorded a charge of approximately $6.1 related to the impairment of two equity investments, both of which are now fully impaired.
v3.25.0.1
Income Taxes
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The components of the Provision (benefit) for income taxes by jurisdiction were as follows:
Year Ended December 31,
202420232022
Current
U.K.$2.3 $(1.2)$9.7 
U.S. Federal19.0 14.5 (1.1)
U.S. State3.1 4.4 2.8 
Other36.8 (40.8)25.4 
Total current61.2 (23.1)36.8 
Deferred
U.K.0.8 (0.4)2.2 
U.S. Federal
(20.0)(30.5)(56.0)
U.S. State(3.2)(4.4)(3.8)
Other44.1 (42.9)(8.1)
Total deferred
21.7 (78.2)(65.7)
Provision (benefit) for income taxes$82.9 $(101.3)$(28.9)
The components of Income (loss) before income tax were as follows:
Year Ended December 31,
202420232022
U.K. income (loss)$(155.4)$(180.1)$174.7 
U.S. income (loss)(437.8)(477.9)(3,721.5)
Other income (loss)39.4 (354.5)(442.3)
Income (loss) before income tax$(553.8)$(1,012.5)$(3,989.1)
While we are a public limited company incorporated under the laws of Jersey, Channel Islands, we are a tax resident of the United Kingdom. The following table presents a reconciliation between the statutory U.K. income tax rate and our effective tax rate:
Year Ended December 31,
202420232022
Income (loss) before income tax$(553.8)$(1,012.5)$(3,989.1)
Provision (benefit) for income taxes82.9 (101.3)(28.9)
Statutory rate25.0 %23.5 %19.0 %
Effect of different tax rates(0.6)%— %1.5 %
BEAT(1.2)%(0.7)%(0.2)%
Change in tax law
(9.6)%— %— %
Valuation allowances
(2.2)%(4.4)%(15.2)%
Share-based compensation(2.4)%(1.3)%(0.2)%
Other permanent differences(1.2)%(0.6)%— %
Withholding tax(0.7)%(0.5)%— %
Uncertain tax positions
(0.9)%7.0 %0.4 %
Outside basis difference in foreign subsidiary
(1.6)%2.1 %(0.1)%
Impairments(18.8)%(15.4)%(6.0)%
Divestitures
(1.1)%— %1.3 %
Tax credits
1.8 %0.6 %0.1 %
Other(1.5)%(0.3)%0.1 %
Effective tax rate
(15.0)%10.0 %0.7 %
The income tax provision of $82.9 for the year ended December 31, 2024 was primarily driven by a $53.9 expense related to a new 15% corporate income tax enacted by a tax law change in Jersey, Channel Islands, a $10.2 expense to establish valuation allowances, and expenses from the mix of tax jurisdictions in which pre-tax profits and losses were recognized. These were partially offset by benefits of $16.6 and $14.2 associated with the impairment of intangible assets and goodwill, respectively.
The income tax benefit of $101.3 for the year ended December 31, 2023 was driven by a $70.4 benefit recorded on the settlement of an open tax dispute (inclusive of indirect tax impacts, interest, and penalties), benefits of $33.0 and $22.7 associated with the impairment of intangible assets and goodwill, respectively, and a $21.2 benefit relating to the partial release of valuation allowances. These primary components resulting in the overall income tax benefit were partially offset by expenses from the mix of tax jurisdictions in which pre-tax profits and losses were recognized.
Deferred Tax Assets and Liabilities
The tax effects of the significant components of temporary differences giving rise to our deferred income tax assets and liabilities were as follows:
December 31,
20242023
Accounts receivable$1.9 $3.6 
Accrued expenses12.2 12.2 
Deferred revenue0.9 2.0 
Partnerships outside basis difference
40.9 68.1 
Other assets24.0 44.4 
Debt issuance costs10.4 11.5 
Lease liabilities8.4 10.6 
Goodwill
527.4 567.1 
Operating losses and tax attributes835.4 717.9 
Total deferred tax assets1,461.5 1,437.4 
Valuation Allowances
(1,279.7)(1,256.6)
Net deferred tax assets181.8 180.8 
Other identifiable intangible assets, net(365.1)(338.9)
Other liabilities(20.9)(16.1)
Right-of-use assets
(5.4)(6.8)
Fixed assets, net(15.2)(21.9)
Total deferred tax liabilities(406.6)(383.7)
Net deferred tax liabilities$(224.8)$(202.9)
Deferred tax assets and liabilities are presented net in the Consolidated Balance Sheets if they are in the same jurisdiction. The components of the net deferred tax liability, as reported in the Consolidated Balance Sheets, were as follows:
December 31,
20242023
Deferred tax asset$48.5 $46.7 
Deferred tax liability(273.3)(249.6)
Net deferred tax liability$(224.8)$(202.9)
We are required to assess the realization of our deferred tax assets and the need for a valuation allowance. The assessment requires judgment on the part of management with respect to benefits that could be realized from future taxable income. The valuation allowance was $1,279.7 and $1,256.6 as of December 31, 2024 and 2023, respectively, against certain deferred tax assets, as it more likely than not that such amounts will not be fully realized. During the years ended December 31, 2024 and 2023, the valuation allowance increased by $23.1 and $77.3, respectively.
As of December 31, 2024, we had U.S. federal tax loss carryforwards of $1,698.8, U.K. tax loss carryforwards of $475.0, U.S. state tax loss carryforwards of $923.5, Japan tax loss carryforwards of $40.4, and tax loss carryforwards in other foreign jurisdictions of $145.9. The carryforward period for U.S. federal tax losses is twenty years for losses generated in tax years ended prior to December 31, 2017. The expiration period for these losses begins in 2036. For U.S. losses generated in tax years beginning after January 1, 2018, the carryforward period is indefinite. The carryforward period for the U.K. tax losses is indefinite. The carryforward period for U.S. state losses varies, and the expiration period is between 2024 and 2043. The carryforward period for the Japan tax losses is nine years, and the expiration period begins in 2025. The carryforward period of other losses varies by jurisdiction. As of December 31, 2024, we also had R&D and other tax credit carryforwards of $25.5 that have various carryforward periods, and the expiration period begins in 2027.
We have provided income taxes and withholding taxes in the amount of $12.5 on the undistributed earnings of foreign subsidiaries as of December 31, 2024. In general, we are not permanently reinvesting our foreign earnings offshore.
Deferred Tax Valuation Allowance
The following table summarizes the changes in our deferred tax valuation allowance:
December 31,
202420232022
Beginning balance, January 1
$1,256.6 $1,179.3 $546.8 
Change charged to expense/(income)
31.1 51.4 657.5 
Change charged to CTA
(8.0)25.9 (17.0)
Change charged to goodwill
— — (8.0)
Ending balance, December 31
$1,279.7 $1,256.6 $1,179.3 
Uncertain Tax Positions
Unrecognized tax benefits represent the difference between the tax benefits that we are able to recognize for financial reporting purposes and the tax benefits that have been recognized, or are expected to be recognized, in filed tax returns. The total amount of net unrecognized tax benefits that, if recognized, would impact our effective tax rate was $30.8 and $26.0 as of December 31, 2024 and 2023, respectively.
We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of December 31, 2024 and 2023, the amount accrued was $3.2 and $2.6, respectively. Interest and penalties recognized for the years ended December 31, 2024, 2023, and 2022 were $0.7, $(23.2), and $3.0. We estimate possible changes to our uncertain tax positions within the next twelve months to be approximately $1.2.
We file income tax returns in the U.K., the U.S., and various other jurisdictions. As of December 31, 2024, our open tax years subject to examination were 2016 through 2023, which includes the major jurisdictions in the U.K. and the U.S.
The following table summarizes our unrecognized tax benefits, excluding interest and penalties:
December 31,
202420232022
Beginning balance, January 1
$26.0 $83.8 $100.2 
Increases for tax positions taken in prior years3.3 1.1 2.9 
Increases for tax positions taken in the current year2.1 1.6 1.5 
Increases for acquisitions (recorded against goodwill)— — 1.4 
Decreases for tax positions taken in prior years(0.5)(54.1)(19.3)
Decreases related to settlements with tax authorities
— (6.2)— 
Decreases due to statute expirations(0.1)(0.2)(2.9)
Ending balance, December 31
$30.8 $26.0 $83.8 
v3.25.0.1
Earnings Per Share
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The basic and diluted EPS computations for our ordinary shares are calculated as follows:
Year Ended December 31,
202420232022
Basic EPS
Net income (loss)
$(636.7)$(911.2)$(3,960.2)
Dividends on preferred shares31.3 75.4 75.4 
Net income (loss) attributable to ordinary shares$(668.0)$(986.6)$(4,035.6)
Weighted average shares, basic
693.6 671.6 676.1 
Basic EPS$(0.96)$(1.47)$(5.97)
Diluted EPS
Net income (loss) attributable to ordinary shares$(668.0)$(986.6)$(4,035.6)
Change in fair value of private placement warrants— — (197.6)
Net income (loss) attributable to ordinary shares, diluted$(668.0)$(986.6)$(4,233.2)
Weighted average shares, basic
693.6 671.6 676.1 
Weighted average effect of potentially dilutive shares
— — 2.5 
Weighted average shares, diluted
693.6 671.6 678.6 
Diluted EPS$(0.96)$(1.47)$(6.24)
Potential ordinary shares on a gross basis, related to share-based awards and private placement warrants were excluded from diluted EPS in each period presented as their inclusion would have been anti-dilutive. Potential shares of 20.2 million, 32.7 million, and 11.0 million were excluded for the years ended December 31, 2024, 2023, and 2022, respectively. For additional information, see Note 11 - Private Placement Warrants and Note 12 - Share-based Compensation.
As a result of the MCPS conversion described in Note 10 - Shareholders' Equity, during the year ended December 31, 2024, the converted MCPS shares were included in basic EPS for the period subsequent to the conversion. Prior to the conversion, the MCPS shares were evaluated for inclusion in diluted EPS using the if-converted method and, in each period presented, were excluded from diluted EPS as their inclusion would have been antidilutive.
v3.25.0.1
Segment Information
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Information Segment Information
As discussed in Note 1 - Nature of Operations and Summary of Significant Accounting Policies, we have organized our business into the following three reportable segments, based on the different products and services we offer and the markets we serve:
Academia & Government. Working with the scientific and academic community, we empower institutions and libraries to drive research excellence and student outcomes by connecting trusted content, deep expertise, and responsible innovation. Our A&G segment is home to research, education, and library solutions, including Web of Science, ProQuest, Ex Libris, and Innovative.
Intellectual Property. Our comprehensive intellectual property data, software, and expertise helps companies drive innovation, law firms achieve practice excellence, and organizations worldwide effectively manage and protect critical IP assets. Our IP segment is home to Derwent Innovation, CompuMark, Innography, IPfolio, FoundationIP, and other IP solutions.
Life Sciences & Healthcare. Our connected data, deep expertise, and intelligence platforms empower life sciences and healthcare organizations with the contextual intelligence needed to deliver safe, effective, and commercially successful treatments and solutions to patients faster. Our LS&H segment is home to comprehensive solutions used by pharma, biotech, and medtech companies, including Cortellis, Medtech, Market Access and Commercialization, and deep consulting expertise.
Our chief operating decision maker (“CODM”) is our chief executive officer (“CEO”), who evaluates performance for our reportable segments based primarily on revenues and Adjusted EBITDA. Our CEO uses these measures predominantly during the annual budgeting process and the quarterly forecast update and reporting process to identify and evaluate investment decisions that provide the best opportunities to accelerate revenue growth and provide incremental margin improvement. Our CEO does not review assets by segment for the purpose of assessing performance or allocating resources due to the significant amount of intangible assets acquired through business combinations, as well as the centralized nature of our working capital management functions.
Significant segment expenses include people-related costs, royalties and other product costs, technology costs (comprised primarily of software licenses and hosting costs), and outside service costs (comprised primarily of professional services and contracted labor). Other costs primarily include facilities costs and product marketing costs.
Adjusted EBITDA represents Net income (loss) before the Provision (benefit) for income taxes, Depreciation and amortization, and Interest expense, net, adjusted to exclude share-based compensation, impairments, restructuring expenses, the impact of certain non-cash fair value adjustments on financial instruments, acquisition and/or disposal-related transaction costs, unrealized foreign currency gains/losses, legal settlements, and other items that are included in Net income (loss) for the period that we do not consider indicative of our ongoing operating performance.
The following table summarizes reportable segment revenues, expenses, and profit and provides a reconciliation of total reportable segment Adjusted EBITDA to Net income (loss) for the periods indicated:
Year Ended December 31,
202420232022
Academia & Government
Revenues
$1,326.4 $1,323.3 $1,280.1 
People-related costs
(349.7)(352.8)(379.1)
Royalties and other product costs
(248.5)(247.7)(253.1)
Technology costs
(80.5)(75.6)(69.6)
Outside service costs
(39.9)(43.0)(46.2)
Other costs
(44.0)(45.7)(46.6)
A&G Adjusted EBITDA
$563.8 $558.5 $485.5 
Intellectual Property
Revenues$811.4 $862.7 $927.1 
People-related costs(283.3)(277.7)(272.8)
Royalties and other product costs(76.1)(91.3)(113.5)
Technology costs(46.3)(44.6)(43.0)
Outside service costs(21.1)(22.7)(28.7)
Other costs(26.1)(26.0)(26.1)
IP Adjusted EBITDA
$358.5 $400.4 $443.0 
Life Sciences & Healthcare
Revenues$418.9 $442.8 $452.6 
People-related costs(190.8)(188.0)(170.0)
Royalties and other product costs(37.6)(43.5)(42.5)
Technology costs(27.1)(24.5)(21.6)
Outside service costs(13.0)(14.4)(20.6)
Other costs(12.3)(14.1)(13.7)
LS&H Adjusted EBITDA
$138.1 $158.3 $184.2 
Total Reportable Segments
Revenues$2,556.7 $2,628.8 $2,659.8 
People-related costs(823.8)(818.5)(821.9)
Royalties and other product costs(362.2)(382.5)(409.1)
Technology costs(153.9)(144.7)(134.2)
Outside service costs(74.0)(80.1)(95.5)
Other costs(82.4)(85.8)(86.4)
Total Reportable Segments Adjusted EBITDA$1,060.4 $1,117.2 $1,112.7 
Reconciliation to net income (loss)
Benefit (provision) for income taxes(82.9)101.3 28.9 
Depreciation and amortization(727.0)(708.3)(710.5)
Interest expense, net(283.4)(293.7)(270.3)
Share-based compensation expense(60.6)(108.9)(102.2)
Goodwill and intangible asset impairments(540.7)(979.9)(4,449.1)
Restructuring and lease impairments(19.6)(40.0)(66.7)
Fair value adjustment of warrants5.2 15.9 206.8 
Transaction related costs(17.9)(8.2)(14.2)
Other(1)
29.8 (6.6)304.4 
Net income (loss)$(636.7)$(911.2)$(3,960.2)
(1) Includes the net impact of unrealized foreign currency gains and losses and other items that do not reflect our ongoing operating performance. This amount includes a net gain on sale of $54.7 from divestitures in 2024, a gain of $49.4 related to a legal settlement in 2023, and a gain on sale of $278.5 from a divestiture in 2022. See Note 2 - Acquisitions and Divestitures and Note 17 - Commitments and Contingencies for further details.
Long-Lived Assets by Geography
The following table summarizes our long-lived assets by geography, based on physical location. Long-lived assets consists of Property and equipment, net and Operating lease right-of-use assets and excludes Goodwill, Other intangible assets, net, Deferred income taxes, and Other assets.
Year Ended December 31,
20242023
U.S.
$35.0 $41.0 
U.K.
18.1 20.1 
India
18.9 9.1 
All other
35.1 36.6 
Total long-lived assets$107.1 $106.8 
v3.25.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Lawsuits and Legal Claims
We are engaged in various legal proceedings, claims, audits, and investigations that have arisen in the ordinary course of business. These matters may include among others, antitrust/competition claims, intellectual property infringement claims, employment matters, and commercial matters. The outcome of the matters against us are subject to future resolution, including the uncertainties of litigation.
From time to time, we are involved in litigation in the ordinary course of our business, including claims or contingencies that may arise related to matters occurring prior to our acquisition of businesses. At the present time, primarily because the matters are generally in early stages, we can give no assurance as to the outcome of any pending litigation to which we are currently a party, and we are unable to determine the ultimate resolution of these matters or the effect they may have on us.
We have and will continue to vigorously defend ourselves against these claims. We maintain appropriate levels of insurance, which we expect are likely to provide coverage for some of these liabilities or other losses that may arise from these litigation matters.
During the year ended December 31, 2023, we reached settlement related to a large legal claim, which was covered by insurance. We recognized a total gain on settlement of $49.4 which is included in Other operating expense (income), net in the Consolidated Statement of Operations.
Between January and March 2022, three putative securities class action complaints were filed in the United States District Court for the Eastern District of New York against Clarivate and certain of its executives and directors alleging that there were weaknesses in the Company’s internal controls over financial reporting and financial reporting procedures that it failed to disclose in violation of federal securities law. The complaints were consolidated into a single proceeding on May 18, 2022. On August 8, 2022, plaintiffs filed a consolidated amended complaint, seeking damages on behalf of a putative class of shareholders who acquired Clarivate securities between July 30, 2020, and February 2, 2022, and/or acquired Clarivate ordinary or preferred shares in connection with offerings on June 10, 2021, or Clarivate ordinary shares in connection with a September 13, 2021, offering. The amended complaint, like the prior complaints, references an error in the accounting treatment of an equity plan included in the Company’s 2020 business combination with CPA Global that was disclosed on December 27, 2021, and related restatements issued on February 3, 2022, of certain of the Company’s previously issued financial statements. The amended complaint also alleges that the Company and certain of its executives and directors made false or misleading statements relating to the Company’s product quality and expected organic revenues and organic growth rate, and that they failed to disclose significant known changes to the Company’s business model. Defendants moved to dismiss the amended complaint on October 7, 2022. Without deciding the motion, the court entered an order on June 23, 2023, allowing plaintiffs limited leave to amend, and plaintiffs filed an amended complaint on July 14, 2023. On August 10, 2023, the court issued an order deeming defendants’ prior motions and briefs to be directed at the amended complaint and permitting defendants to file supplemental briefs to address the new allegations in the amended complaint. Supplemental briefing on the motions was completed on September 8, 2023. Defendants’ motions to dismiss the amended complaint are currently pending.
In a separate but related litigation, on June 7, 2022, a class action was filed in Pennsylvania state court in the Court of Common Pleas of Philadelphia asserting claims under the Securities Act of 1933, based on substantially similar allegations, with respect to alleged misstatements and omissions in the offering documents for two issuances of Clarivate ordinary shares in June and September 2021. The Company moved to stay this proceeding on August 19, 2022, and filed its preliminary objections to the state court complaint on October 21, 2022. After granting a partial stay on January 4, 2023, the court denied a further stay of the proceedings on April 17, 2023. On April 24, 2024, the court sustained the Company’s preliminary objections, but permitted plaintiff leave to file an amended complaint, which plaintiff filed on May 28, 2024. On August 29, 2024, plaintiff filed a second amended complaint, to which the Company filed preliminary objections on September 30, 2024. Clarivate does not believe that the claims alleged in the complaints have merit and will vigorously defend against them. Given the early stage of the proceedings, we are unable to estimate the reasonably possible loss or range of loss, if any, arising from these matters.
v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net income (loss) $ (636.7) $ (911.2) $ (3,960.2)
v3.25.0.1
Insider Trading Arrangements
3 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2024
Trading Arrangements, by Individual    
Material Terms of Trading Arrangement  
During the quarter ended December 31, 2024, no director or officer (as defined in Rule 16a-1 under the Exchange Act) of the Company adopted or terminated a Rule 10b5-1 trading plan or adopted or terminated a non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408(a) of Regulation S-K).
Rule 10b5-1 Arrangement Adopted false  
Non-Rule 10b5-1 Arrangement Adopted false  
Rule 10b5-1 Arrangement Terminated false  
Non-Rule 10b5-1 Arrangement Terminated false  
v3.25.0.1
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
At Clarivate, cybersecurity risk management is an integral part of our Enterprise Risk Management program. Because we are a global information services provider, our business is highly dependent on the protection of our proprietary software and content, as well as the timeliness, accuracy, and availability of our offerings. Consequently, we are highly sensitive to risks from cybersecurity threats to our information systems, particularly those threats that would affect our ability to continue to provide real-time access to our database content and analysis. To mitigate these threats, we utilize the following processes and governance structure.
Our Information Security Risk Management program is based on recognized industry governance frameworks, including the International Organization for Standardization. It provides a framework to identify, assess, and control cybersecurity threats and incidents. We perform an annual information security risk assessment with the assistance of independent security companies, with the aim to embed information security principles and objectives into our culture, business operations, and support functions.
Our cybersecurity efforts also include mandatory information security awareness training for all employees, clearly defined expectations for acceptable use policies, and certification of adherence to a code of conduct. The IT Governance, Risk, and Compliance team conducts periodic audits to evaluate policy and regulatory compliance, recording findings for subsequent review and remediation initiatives. We also leverage internal and external security subject matter experts to conduct comprehensive risk assessments, including architecture reviews, vulnerability scans, penetration tests, application security evaluations, and technical compliance reviews.
We maintain a security threat intelligence system that collects and analyzes data from internal vulnerability management tools, vendors, and third-party security organizations. Our patch management standard is designed to ensure that appropriate patching practices are consistently applied to our technology infrastructure, and a Security Operations Center enhances our real-time awareness, event correlation, and incident response capabilities.
As part of our risk management program, we also assess cybersecurity risks associated with third-party service providers. We have processes in place to oversee and identify material risks from cybersecurity threats associated with our engagement of such providers, including the use of cybersecurity risk criteria when determining the selection and oversight of those service providers.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
At Clarivate, cybersecurity risk management is an integral part of our Enterprise Risk Management program. Because we are a global information services provider, our business is highly dependent on the protection of our proprietary software and content, as well as the timeliness, accuracy, and availability of our offerings. Consequently, we are highly sensitive to risks from cybersecurity threats to our information systems, particularly those threats that would affect our ability to continue to provide real-time access to our database content and analysis. To mitigate these threats, we utilize the following processes and governance structure.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Our cybersecurity efforts also include mandatory information security awareness training for all employees, clearly defined expectations for acceptable use policies, and certification of adherence to a code of conduct.
Cybersecurity Risk Board of Directors Oversight [Text Block]
The Board of Directors, acting directly and through its committees, is responsible for the oversight of our risk management programs. The Board’s Audit Committee has the delegated responsibility for the oversight of key enterprise risks, including risks from cybersecurity threats. The committee also provides oversight of our policies and processes for monitoring and mitigating such risks. Among other duties, the Audit Committee receives and reviews periodic reports from management pertaining to cybersecurity programs and data protection controls, as well as other information security reports that the committee deems appropriate. The committee meets at least quarterly, and the chair of the committee gives regular reports to the full Board of Directors on its activities.
Management is responsible for day-to-day risk management activities, including those relating to information systems and cybersecurity. We employ an internal chief information security officer (“CISO”) who has more than 25 years of technology industry leadership, cybersecurity expertise, and engineering and operations experience. Our CISO and his team of certified security subject matter experts (collectively, “Information Security”) have deep experience and expertise in cybersecurity and lead our organizational efforts to assess and manage material risks associated with our information systems and cybersecurity threats. Our dedicated Information Security Steering Committee regularly reviews our most significant information security risks, strategic projects, and key performance indicators. On a quarterly basis, Information Security also meets with business segment leadership to discuss the most significant risks, including identifying potentially material risks and developing, implementing, and applying reasonable risk mitigation processes.
Our risk management programs are developed, implemented, managed, and reviewed at the direction of Information Security and business segment leaders, with subsequent actions determined based on the results of these preventive and detective controls. We have implemented incident response procedures that define our approach when potential security incidents are identified, with clear definition of the escalation path, including when notification to the Audit Committee is required. Depending on the assessed severity of the incident, the Audit Committee may be notified immediately or at its next regularly scheduled meeting.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Board of Directors
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] The committee meets at least quarterly, and the chair of the committee gives regular reports to the full Board of Directors on its activities.
Cybersecurity Risk Role of Management [Text Block] The committee also provides oversight of our policies and processes for monitoring and mitigating such risks.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Board of Directors
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our risk management programs are developed, implemented, managed, and reviewed at the direction of Information Security and business segment leaders, with subsequent actions determined based on the results of these preventive and detective controls.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] We have implemented incident response procedures that define our approach when potential security incidents are identified, with clear definition of the escalation path, including when notification to the Audit Committee is required.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and include our accounts and the accounts of our wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Certain reclassifications of prior period amounts have been made to conform to the current period presentation.
Recently Issued Accounting Standards
Recently Issued Accounting Standards
In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which is designed to provide greater income tax disclosure transparency by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments in this update are effective for fiscal years beginning after December 15, 2024 on a prospective basis. Early adoption is permitted. We are currently assessing the impact of this update on our related disclosures.
In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires footnote disclosure that disaggregates relevant expense captions, including the total amount of selling expenses. The amendments in this update are effective for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027 on a prospective basis, with the option for retrospective application. Early adoption is permitted. We are currently assessing the impact of this update on our financial statement disclosures.
Foreign Currency Translation
Foreign Currency Translation
The operations of each of our entities are measured using the currency of the primary economic environment in which the subsidiary operates (“functional currency”). Assets and liabilities of foreign subsidiaries whose functional currency is the local currency are translated into U.S. dollars using period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect during each fiscal month during the year. The effects of foreign currency translation adjustments are included as a component of Accumulated other comprehensive income (loss) in the accompanying Consolidated Balance Sheets.
Restructuring
Restructuring
Restructuring expense includes costs associated with involuntary termination benefits provided to employees, certain contract termination costs, and other costs associated with an exit or disposal activity. Involuntary termination benefits are recognized within restructuring charges at the time that the program was approved and all necessary communications were made. The liabilities are recorded within Accrued expenses and other current liabilities in the Consolidated Balance Sheets. The corresponding expenses are recorded within Restructuring and other impairments in the Consolidated Statements of Operations. For further details, see Note 13 - Restructuring and Other Impairments.
Treasury Shares
Treasury Shares
Treasury share purchases, whether through share withholdings for taxes or repurchase programs and transactions, are recorded at cost. Issuances from treasury shares are recorded using the First In, First Out (“FIFO”) method.
Significant Judgments
When multiple performance obligations exist in a single contract, the transaction price is allocated to each performance obligation in proportion to the standalone selling price of each performance obligation. The standalone selling price is typically determined by reference to our standard price lists and is a reflection of our normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. Discounts applied to the contract are allocated based on the same proportion of standalone selling prices.
Earnings Per Share
Earnings Per Share
Basic earnings per share (“EPS”) is calculated by dividing net income (loss) attributable to ordinary shares by the weighted average number of ordinary shares outstanding for the applicable period. Diluted EPS is computed by dividing net income (loss) attributable to ordinary shares, adjusted for the change in fair value of the private placement warrants, by the weighted average number of ordinary shares and dilutive potential ordinary shares outstanding for the applicable period. Diluted EPS reflects the potential dilution that could occur if securities were exercised or converted into ordinary shares, as calculated using the treasury stock method.
Legal Costs
Legal Costs
Legal costs expected to be incurred in connection with a loss contingency are expensed and accrued at the outset of the legal matter giving rise to the estimated legal costs. We reassess the sufficiency of the accrual each reporting period.
Defined Contribution Plans
Defined Contribution Plans
Employees participate in various defined contribution savings plans that provide for Company-matching contributions. Costs for future employee benefits are accrued over the periods in which employees earn the benefits. Total expense related to defined contribution plans was $37.3, $34.9, and $30.5 for the years ended December 31, 2024, 2023, and 2022, respectively, which approximates the cash outlays related to the plans.
Share-Based Compensation
Share-based Compensation
We recognize compensation expense for share-based awards based on grant date fair value. The fair value of RSUs is based on the fair value of our common shares on the date of grant, and we use a Monte Carlo simulation to determine the fair value of our PSUs at grant date. We use the graded vesting method to amortize the value of share-based awards to expense. We recognize forfeitures as they occur.
Cost to Obtain a Contract
We pay commissions to sales managers and support teams for earning new customers and renewing contracts with existing customers. We treat these commission costs as costs to obtain a contract and are therefore considered contract assets. We capitalize certain of these commission costs within Prepaid expenses and Other non-current assets on the Consolidated Balance Sheets. The costs are amortized to Selling, general and administrative costs within the Consolidated Statements of Operations. The amortization period is between one and seven years based on the estimated length of the customer relationship.
Revenue Recognition
Revenue Recognition
We derive revenue through subscriptions to our product offerings, re-occurring contracts in our IP segment, and transactional sales that are typically quoted on a product, data set, or project basis.
Subscription-based revenues are recurring revenues that we typically earn under annual contracts, pursuant to which we license the right to use our products to our customers or provide maintenance services over a contractual term. We invoice and collect the subscription fee at the beginning of the subscription period. For multi-year agreements, we generally invoice customers annually at the beginning of each annual coverage period. Cash received or receivable in advance of completing the performance obligations is included in deferred revenue. We recognize subscription revenue ratably over the contract term as the access or service is provided.
Re-occurring revenues are derived solely from the patent and trademark maintenance services provided by our IP segment. Patents and trademarks are renewed regularly, and our services help customers maintain and protect those patents and trademarks in multiple jurisdictions around the world. Because of the re-occurring nature of the patent and trademark lifecycle, our customer base engages us to manage the renewal process on their behalf. These contracts typically include evergreen clauses or are multi-year agreements. We invoice and recognize revenue upon delivery of the service.
Transactional revenues are earned for specific deliverables that are typically quoted on a product, data set, or project basis. Transactional revenues include content sales (including single-document and aggregated collection sales), consulting engagements, and other professional services such as software implementation services. We typically invoice and record revenue for this revenue stream upon delivery of the product, data set, or project, although for longer software implementation projects, we will periodically invoice and recognize revenue in connection with the completion of related performance obligations.
For transactions that involve a third party, we evaluate whether we are acting as the principal or the agent in the transaction by considering factors such as control of the specified goods or services before they are transferred to the customer, fulfillment responsibility, collection risk, and discretion in establishing price. If we determine that we control the good or service before it is transferred to the customer, we recognize revenue on a gross basis. Conversely, if we determine that we do not control the good or service before it is transferred to the customer, we recognize revenue on a net basis.
Income Taxes
Income Taxes
We recognize income taxes under the asset and liability method. Deferred income tax assets and liabilities arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred income tax assets and liabilities are recorded at the enacted tax rate expected to apply to the temporary difference when settled or realized. We record U.S. tax expense resulting from Global Intangible Low Taxed Income (“GILTI”) as a current period expense.
In assessing the realizability of deferred tax assets, we consider all available positive and negative evidence factors. Evidence considered includes historical and projected future taxable income by tax jurisdiction, character and timing of income or loss, and prudent and feasible tax planning strategies. We record a valuation allowance to reduce deferred tax assets to the net realizable value that is more likely than not to be realized.
We record tax benefits when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. The amount of tax benefit recorded is the largest amount of tax benefit that is greater than 50% likely to be realized upon settlement. We then record a liability for unrecognized tax benefits resulting from uncertain tax positions taken or expected to be taken on a tax return. Uncertain tax positions are reassessed quarterly and liabilities for unrecognized tax benefits are adjusted when our judgment changes as a result of the evaluation of new information, such as developments in case law, new regulations or tax law, or changes in the status of ongoing audits. These adjustments will be reflected as increases or decreases to income tax expense in the period in which new information is available. Accrued interest and penalties related to unrecognized tax benefits are included within the Provision (benefit) for income taxes in the Consolidated Statements of Operations.
Impairment of Long-lived Assets
Impairment of Long-Lived Assets
We evaluate our long-lived assets, including property and equipment, internally developed software and content, definite-lived intangible assets, and operating lease ROU assets for impairment whenever circumstances indicate the carrying value may not be recoverable. We determine the recoverability of a long-lived asset, or a group of similar long-lived assets, by comparing its carrying value to the future undiscounted cash flows that the asset is expected to generate over its remaining life. Any impairment is measured as the difference between the carrying value and the fair value of the asset.
Goodwill and Indefinite-Lived Intangible Assets
Goodwill and indefinite-lived intangible assets are not amortized, but instead are tested for impairment annually as of the first day of the fourth quarter, or more frequently if events or changes in circumstances indicate that the asset might be impaired.
Goodwill impairment testing is performed at the reporting unit level. For goodwill impairment testing purposes, we have determined that our business segments are our reporting units. As part of our annual goodwill impairment testing, we have the option to first perform qualitative testing to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If we bypass the qualitative assessment, or if the qualitative assessment indicates that quantitative analysis should be performed, we evaluate goodwill for impairment by comparing the estimated fair value of a reporting unit with its carrying amount, including goodwill. We estimate the fair value of a reporting unit using a discounted cash flow (“DCF”) analysis based on the present value of estimated future cash flows, discounted at an appropriate risk-adjusted rate. We use our internal forecasts to estimate future cash flows and include an estimate of long-term future growth rates.
Our indefinite-lived intangible assets are related to trade names. Similar to goodwill, as part of our annual indefinite-lived intangible asset impairment testing, we have the option to first perform qualitative testing by evaluating whether any events and circumstances occurred that provide evidence that it is more likely than not that the indefinite-lived assets are impaired. If we do not believe that it is more likely than not that the indefinite-lived assets are impaired, no quantitative impairment test is required. If we choose not to complete a qualitative assessment, or if the qualitative assessment indicates that a quantitative analysis should be performed, we estimate the fair value of the indefinite-lived asset by using the relief-from-royalty method based on the present value of estimated future cash flows that the indefinite-lived asset is expected to generate in the future.
Assets to be disposed of are carried at the lower of their financial statement carrying amount or fair value, less cost to sell.
Any impairment charge is recognized in full in the reporting period in which it has been identified. For discussion of the analysis and results of our impairment tests, see Note 6 - Other Intangible Assets, Net and Goodwill and Note 13 - Restructuring and Other Impairments.
Identifiable Intangible Assets, net
Definite-lived intangible assets are generally amortized on a straight-line basis over the following estimated useful lives:
Customer relationships
2 - 23 years
Technology and content
2 - 20 years
Computer software5 years
Trade names and other
2 - 18 years
Business Combinations We account for our business combinations using the acquisition method of accounting. We allocate the purchase price of an acquisition to the assets acquired and liabilities assumed based on their estimated fair values. As part of this allocation process, we identify and attribute values and estimated lives to the intangible assets acquired. The excess of the purchase price over the fair values of identifiable assets and liabilities is recorded as goodwill.
Leases
Leases
We determine if an arrangement is a lease at inception. Operating leases are included in Operating lease right-of-use (“ROU”) assets, Current portion of operating lease liability, and Operating lease liabilities on our Consolidated Balance Sheets. Our finance lease asset is included within Property and equipment, net on our Consolidated Balance Sheets (see Note 5 - Property and Equipment, Net) and the related finance lease liability is included as an item of indebtedness (see Note 9 - Debt) on our Consolidated Balance Sheets.
Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The initial valuation of finance lease assets and liabilities is calculated in the same way. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.
We account for lease and non-lease components as a single lease component.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents is comprised of cash on hand and short-term deposits with an original maturity at the date of purchase of three months or less, and includes restricted cash of $10.5 and $12.9 as of December 31, 2024 and 2023, respectively.
Fair Value Measurements
Fair Value Measurements
Fair value is determined based on the assumptions that market participants would use in pricing the asset or liability. We utilize the following fair value hierarchy in determining fair values:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.
Level 3 - Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies, and similar techniques that use significant unobservable inputs.
The carrying value of cash and cash equivalents, accounts receivable, accounts payable, and other accruals readily convertible into cash approximate fair value because of the short-term nature of the instruments. As further discussed in Note 2 - Acquisitions and Divestitures, we have classified the contingent consideration associated with the Valipat divestiture within Level 3 of the fair value hierarchy. As further discussed in Note 9 - Debt, we have classified our debt instruments within Level 2 of the fair value hierarchy. We have also classified our derivative instruments described in Note 8 - Derivative Instruments within Level 2 of the fair value hierarchy.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the Consolidated Financial Statements and accompanying notes. Actual results could differ from those estimates. The most significant of these estimates relate to the initial valuation of acquired long-lived and intangible assets and goodwill, subsequent impairment analyses, and income taxes. We evaluate these estimates, assumptions, and judgments on an ongoing basis by reference to our historical experience and other factors, including expectations of future events that we believe are reasonable under the circumstances.
Allowance for Credit Losses
Allowance for Credit Losses
We estimate credit losses for trade receivables by using a current expected credit loss model. The credit loss allowance is determined through an analysis of historical collection experience, the aging of accounts receivable, and an evaluation of the impact of current and projected economic conditions. Trade and other receivables are written off when there is no reasonable expectation of recovery, such as a past due status greater than 360 days or bankruptcy of the debtor.
Internally Developed Software and Content
Internally Developed Software and Content
Internally Developed Software — Development costs related to internally generated software are capitalized once a project has progressed to the application development stage. Costs of significant improvements or enhancements on existing software for internal use, both internally developed and purchased, are also capitalized. Costs related to the preliminary project stage, data conversion, and post-implementation/operation stage of an internal-use software development project are expensed as incurred. Capitalized costs are amortized over five years, which is the estimated useful life of the related software. Purchased software is amortized over three years, which is the estimated useful life of the related software.
Content — Costs related to the acquisition of source materials, content selection, document processing, editing, abstracting, and indexing are capitalized. We also capitalize internal and external costs associated with the development of product-related software that adds functionality and improves the customer’s ability to search our content. These capitalized costs are amortized over a two to five year useful life.
We do not capitalize any costs associated with research and development or marketing.
Concentration of Credit Risk
Concentration of Credit Risk
Accounts receivable are the primary financial instrument that potentially subjects us to significant concentrations of credit risk. Accounts receivable represent arrangements in which services were transferred to a customer before the customer pays consideration or before payment is due. We do not require collateral or other securities to support customer receivables. We perform ongoing credit evaluations of our customers and limit the amount of credit extended when deemed appropriate.
We maintain our cash and cash equivalent balances with high-quality financial institutions and consequently, we believe that such funds are subject to minimal credit risk.
Property and Equipment
Property and Equipment
Property and equipment is recorded at cost, and depreciation is recorded using the straight‑line method over the estimated useful lives of the assets, as follows:
Computer hardware3 years
Furniture, fixtures, and equipment
5 - 7 years
Leasehold improvementsLesser of lease term or estimated useful life
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Property and Equipment, Net
Property and equipment is recorded at cost, and depreciation is recorded using the straight‑line method over the estimated useful lives of the assets, as follows:
Computer hardware3 years
Furniture, fixtures, and equipment
5 - 7 years
Leasehold improvementsLesser of lease term or estimated useful life
Property and equipment, net consisted of the following:
December 31,
20242023
Computer hardware$64.3 $54.5 
Leasehold improvements21.6 15.9 
Furniture, fixtures, and equipment
46.6 44.5 
Finance lease
8.0 8.0 
Other2.2 2.3 
Property and equipment, gross$142.7 $125.2 
Accumulated depreciation(89.2)(73.6)
Property and equipment, net$53.5 $51.6 
Schedule of Finite-Lived Intangible Assets
Definite-lived intangible assets are generally amortized on a straight-line basis over the following estimated useful lives:
Customer relationships
2 - 23 years
Technology and content
2 - 20 years
Computer software5 years
Trade names and other
2 - 18 years
Schedule of Accounts Payable and Accrued Liabilities
Accrued expenses and other current liabilities consisted of the following:
December 31,
20242023
Liabilities due to customers$84.8 $62.0 
Accrued royalties79.3 75.4 
Miscellaneous accruals146.0 177.8 
Accrued expenses and other current liabilities$310.1 $315.2 
Schedule of Other Operating (Income) Expense, Net
Other operating expense (income), net consisted of the following:
Year Ended December 31,
202420232022
Gain on sale from divestitures
Note 2$(54.7)$— $(278.5)
Gain on legal settlement
Note 17— (49.4)— 
Net foreign exchange loss (gain)

4.2 38.9 (45.4)
Miscellaneous, net
(1.3)(0.3)(0.9)
Total$(51.8)$(10.8)$(324.8)
v3.25.0.1
Revenue (Tables)
12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregated revenues
The following tables present our revenues by transaction type, based on revenue recognition pattern, and by geography, based on the location of the customer:
Year Ended December 31,
Revenues by transaction type 202420232022
Subscription revenues$1,626.8 $1,618.1 $1,618.8 
Re-occurring revenues429.8 444.6 441.9 
Transactional revenues
500.1 566.1 599.1 
Revenues$2,556.7 $2,628.8 $2,659.8 
Year Ended December 31,
Revenues by geography202420232022
Americas$1,381.4 $1,405.5 $1,462.3 
Europe/Middle East/Africa667.8 707.5 698.3 
APAC507.5 515.8 499.2 
Revenues$2,556.7 $2,628.8 $2,659.8 
Schedule of contract balances
December 31,
20242023
Accounts receivable, net$798.3 $908.3 
Current portion of deferred revenues$859.1 $983.1 
Non-current portion of deferred revenues$16.6 $38.7 
v3.25.0.1
Accounts Receivable (Tables)
12 Months Ended
Dec. 31, 2024
Receivables [Abstract]  
Schedule of Accounts, Notes, Loans and Financing Receivable
Our Accounts receivable, net balance consisted of the following:
December 31,
20242023
Accounts receivable$814.5 $934.9 
Less: Accounts receivable allowance(16.2)(26.6)
Accounts receivable, net$798.3 $908.3 
Accounts Receivable, Allowance for Credit Loss Roll Forward
The change in our accounts receivable allowance related to the following activity during each of the years presented:
Year Ended December 31,
202420232022
Balance at beginning of year$26.6 $27.1 $24.9 
Additional provisions3.2 7.0 10.9 
Write-offs(12.9)(9.3)(7.8)
Exchange differences(0.7)1.8 (0.9)
Balance at end of year
$16.2 $26.6 $27.1 
v3.25.0.1
Property and Equipment, Net (Tables)
12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment, Net
Property and equipment is recorded at cost, and depreciation is recorded using the straight‑line method over the estimated useful lives of the assets, as follows:
Computer hardware3 years
Furniture, fixtures, and equipment
5 - 7 years
Leasehold improvementsLesser of lease term or estimated useful life
Property and equipment, net consisted of the following:
December 31,
20242023
Computer hardware$64.3 $54.5 
Leasehold improvements21.6 15.9 
Furniture, fixtures, and equipment
46.6 44.5 
Finance lease
8.0 8.0 
Other2.2 2.3 
Property and equipment, gross$142.7 $125.2 
Accumulated depreciation(89.2)(73.6)
Property and equipment, net$53.5 $51.6 
v3.25.0.1
Other Intangible Assets, Net and Goodwill (Tables)
12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets
The following tables summarize the gross carrying amounts and accumulated amortization of our identifiable intangible assets by major class:
December 31, 2024December 31, 2023
GrossAccumulated AmortizationNetGrossAccumulated AmortizationNet
Definite-lived intangible assets:
Customer relationships$7,773.9 $(1,515.9)$6,258.0 $7,819.9 $(1,177.2)$6,642.7 
Technology and content2,748.8 (1,204.6)1,544.2 2,798.3 (1,009.1)1,789.2 
Computer software1,060.6 (609.2)451.4 897.9 (516.4)381.5 
Trade names and other
88.4 (57.7)30.7 88.9 (52.6)36.3 
Definite-lived intangible assets
$11,671.7 $(3,387.4)$8,284.3 $11,605.0 $(2,755.3)$8,849.7 
Indefinite-lived intangible assets:
Trade names156.9 — 156.9 156.9 — 156.9 
Total intangible assets$11,828.6 $(3,387.4)$8,441.2 $11,761.9 $(2,755.3)$9,006.6 
Schedule of Weighted-Average Estimated Useful Life for Definite-Lived Intangible Assets
As of December 31, 2024, the remaining weighted-average estimated useful life (in years) of our definite-lived intangible assets, by major class and in total, was as follows:
Customer relationships18
Technology and content9
Computer software6
Trade names and other
7
Total16
Schedule of Estimated Amortization for Five Succeeding Years
As of December 31, 2024, estimated future amortization expense related to definite-lived intangible assets was as follows:
2025$680.2 
2026646.9 
2027612.9 
2028581.3 
2029538.1 
Thereafter5,209.1 
Amortizing intangible assets
$8,268.5 
Internally developed software projects in process15.8 
Definite-lived intangible assets
$8,284.3 
Schedule of Goodwill
The change in the carrying amount of Goodwill by segment was as follows:
A&G
Segment
IP
Segment
LS&H
Segment
Total
Consolidated
Balance as of December 31, 2022$1,109.8 $590.3 $1,176.4 $2,876.5 
Acquisition
— — 3.0 3.0 
Goodwill impairment
— (582.2)(265.5)(847.7)
Impact of foreign currency fluctuations
— (8.1)— (8.1)
Balance as of December 31, 2023$1,109.8 $— $913.9 $2,023.7 
Acquisition— 13.8 15.8 29.6 
Goodwill impairment
— (13.8)(451.9)(465.7)
Divestiture(1)
(20.6)— — (20.6)
Impact of foreign currency fluctuations
(0.4)— — (0.4)
Balance as of December 31, 2024$1,088.8 $— $477.8 $1,566.6 
(1) Related to the ScholarOne divestiture and its allocated portion of the A&G segment reporting unit’s goodwill balance. For further details, see Note 2 - Acquisitions and Divestitures.
v3.25.0.1
Leases (Tables)
12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Lease, Cost
The following table presents the components of our lease cost, supplemental cash flow disclosures, and other information related to our lease arrangements:
Year Ended December 31,
202420232022
Lease Cost:
Operating lease cost$20.2 $22.4 $27.9 
Variable lease cost4.0 5.3 2.5 
Short-term lease cost0.8 0.7 0.4 
Finance lease cost:
     Amortization
0.3 0.5 10.8 
     Interest
2.1 2.1 1.2 
Total lease cost$27.4 $31.0 $42.8 
Supplemental Cash Flow Disclosures:
Cash paid for amounts included in measurement of lease liabilities
Operating cash flows for operating leases$30.3$31.9$34.7
Operating cash flows for finance leases2.12.11.2
Financing cash flows for finance leases1.21.01.9
Right-of-use assets obtained in exchange for lease obligations
Operating leases$16.8$16.2$2.6
Finance leases2.4
Other Information:
Weighted-average remaining lease term
Operating leases555
Finance leases121314
Weighted-average discount rate
Operating leases6.2 %5.2 %4.3 %
Finance leases6.9 %6.9 %6.9 %
Operating Lease Maturity
The following table presents an analysis of our lease liability maturities as of December 31, 2024:
Year Ending December 31,
Operating LeasesFinance Leases
2025$24.4 $3.3 
202618.6 3.4 
202713.7 3.4 
20288.0 3.5 
20296.7 3.6 
Thereafter15.3 26.3 
Total undiscounted cash flows $86.7 $43.5 
Present value:
Current lease liabilities20.6 1.3 
Non-current lease liabilities53.2 28.0 
Total lease liabilities$73.8 $29.3 
Interest on lease liabilities$12.9 $14.2 
Finance Lease Maturity
The following table presents an analysis of our lease liability maturities as of December 31, 2024:
Year Ending December 31,
Operating LeasesFinance Leases
2025$24.4 $3.3 
202618.6 3.4 
202713.7 3.4 
20288.0 3.5 
20296.7 3.6 
Thereafter15.3 26.3 
Total undiscounted cash flows $86.7 $43.5 
Present value:
Current lease liabilities20.6 1.3 
Non-current lease liabilities53.2 28.0 
Total lease liabilities$73.8 $29.3 
Interest on lease liabilities$12.9 $14.2 
v3.25.0.1
Derivative Instruments (Tables)
12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Fair Value of Derivative Instruments
The following table provides information on the location and fair value amounts of our derivative instruments:
December 31,
Balance Sheet Classification20242023
Asset Derivatives
Designated as accounting hedges:
Interest rate swapsOther current assets$— $4.1 
Interest rate swapsOther non-current assets14.7 17.7 
Cross-currency swaps
Other non-current assets3.7 — 
Not designated as accounting hedges:
Foreign currency forwardsOther current assets— 1.3 
Total Asset Derivatives$18.4 $23.1 
Liability Derivatives
Designated as accounting hedges:
Cross-currency swaps
Other non-current liabilities$— $2.0 
Not designated as accounting hedges:
Foreign currency forwardsAccrued expenses and other current liabilities1.1 0.1 
Total Liability Derivatives$1.1 $2.1 
v3.25.0.1
Debt (Tables)
12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
The following table summarizes our total indebtedness:
December 31, 2024December 31, 2023
TypeMaturityEffective
Interest
Rate
Carrying
Value
Effective
Interest
Rate
Carrying
Value
Senior Notes20294.875%$921.4 4.875 %$921.4 
Senior Secured Notes20283.875%921.2 3.875 %921.2 
Senior Secured Notes20264.500%700.0 4.500 %700.0 
Revolving Credit Facility20297.107%— 8.206 %— 
Term Loan Facility 20317.107%1,999.2 8.470 %2,197.4 
Finance lease
20366.936%29.3 6.936 %30.3 
Total debt outstanding$4,571.1 $4,770.3 
Debt discounts and issuance costs(51.1)(48.0)
Current portion of long-term debt(1.3)(1.2)
Long-term debt$4,518.7 $4,721.1 
Debt Instrument Redemption
Redemption Price
(as a percentage of principal)
PeriodSenior Notes (2029)Senior Secured Notes (2028)
2024102.438 %101.938 %
2025101.219 %100.969 %
2026 and thereafter100.000 %100.000 %
Schedule of Maturities of Outstanding Borrowings
Amounts due under our outstanding borrowings as of December 31, 2024 are as follows:
2025$1.3 
2026701.5 
20271.7 
2028923.1 
2029
923.5 
Thereafter2,020.0 
Total maturities$4,571.1 
Less: capitalized debt issuance costs and original issue discount(51.1)
Total, including the current portion of long-term debt$4,520.0 
v3.25.0.1
Shareholders' Equity (Tables)
12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) (“AOCI” or “AOCL”)
The table below provides information about the changes in Accumulated Other Comprehensive Income (Loss) by component and the related amounts reclassified to net earnings during the periods indicated (net of tax). The foreign currency translation adjustment component of AOCL represents the impact of translating foreign subsidiary asset and liability balances from their local currency to USD. The change in each period below was primarily related to foreign subsidiaries whose local currency is GBP.
Interest rate swapsDefined benefit pension plansForeign currency translation adjustmentAccumulated Other Comprehensive Income (Loss)
Balance as of December 31, 2021
$1.1 $(1.4)$327.0 $326.7 
Other comprehensive income (loss) before reclassifications41.1 2.9 (1,032.5)(988.5)
Reclassifications from AOCL to net earnings(4.1)— — (4.1)
Net other comprehensive income (loss)
37.0 2.9 (1,032.5)(992.6)
Balance as of December 31, 2022$38.1 $1.5 $(705.5)$(665.9)
Other comprehensive income (loss) before reclassifications14.9 (1.1)194.2 208.0 
Reclassifications from AOCL to net earnings(36.8)— (0.6)(37.4)
Net other comprehensive income (loss)
(21.9)(1.1)193.6 170.6 
Balance as of December 31, 2023$16.2 $0.4 $(511.9)$(495.3)
Other comprehensive income (loss) before reclassifications16.1 (0.8)(40.4)(25.1)
Reclassifications from AOCL to net earnings(21.6)— 15.7 (5.9)
Net other comprehensive income (loss)
(5.5)(0.8)(24.7)(31.0)
Balance as of December 31, 2024$10.7 $(0.4)$(536.6)$(526.3)
v3.25.0.1
Share-based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Share-based Payment Arrangement, Expensed and Capitalized, Amount
Total share-based compensation expense for the years ended December 31, 2024, 2023, and 2022, comprised the following:
Year Ended December 31,
202420232022
Cost of revenues$14.6 $39.9 $36.3 
Selling, general and administrative costs46.0 69.0 65.9 
Total share-based compensation expense$60.6 $108.9 $102.2 
Total income tax provision (benefit) recognized for stock-based compensation arrangements were as follows:
Year Ended December 31,
202420232022
Provision (benefit) for income taxes$(2.2)$(8.7)$(8.3)
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity
A summary of RSU and PSU activity for the year ended December 31, 2024, is presented below:
Year Ended December 31, 2024
RSUsRSUs Weighted
Average Grant Date Fair Value
PSUsPSUs Weighted
Average Grant Date Fair Value
Outstanding at December 31, 202310.8 $11.89 2.8 $12.95 
Granted9.1 6.892.6 7.77
Vested
(6.6)12.10(0.3)15.15
Forfeited
(1.0)9.55(1.1)9.10
Outstanding at December 31, 202412.3 $8.27 4.0 $10.48 
Total remaining unamortized compensation costs$38.0 $11.4 
Weighted average remaining service period0.91 years1.58 years
Schedule of Nonvested Performance-based Units Activity
A summary of RSU and PSU activity for the year ended December 31, 2024, is presented below:
Year Ended December 31, 2024
RSUsRSUs Weighted
Average Grant Date Fair Value
PSUsPSUs Weighted
Average Grant Date Fair Value
Outstanding at December 31, 202310.8 $11.89 2.8 $12.95 
Granted9.1 6.892.6 7.77
Vested
(6.6)12.10(0.3)15.15
Forfeited
(1.0)9.55(1.1)9.10
Outstanding at December 31, 202412.3 $8.27 4.0 $10.48 
Total remaining unamortized compensation costs$38.0 $11.4 
Weighted average remaining service period0.91 years1.58 years
v3.25.0.1
Restructuring and Other Impairments (Tables)
12 Months Ended
Dec. 31, 2024
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
The following table summarizes the pre-tax charges by activity and program during the periods indicated:
Year Ended December 31,
202420232022
Severance and related benefit costs:
Value Creation Plan
$0.5 $— $— 
Segment Optimization
19.9 13.4 — 
ProQuest Acquisition Integration
(0.1)16.7 22.9 
One Clarivate and other restructuring programs
— — 16.3 
Total Severance and related benefit costs
20.3 30.1 39.2 
Exit and disposal costs:
Value Creation Plan
0.1 — — 
Segment Optimization Program0.3 — — 
ProQuest Acquisition Integration
— 0.2 2.2 
One Clarivate and other restructuring programs
— — 1.0 
Total Exit and disposal costs
0.4 0.2 3.2 
Lease abandonment costs:
Value Creation Plan
— — — 
Segment Optimization
(1.1)3.7 — 
ProQuest Acquisition Integration
— — 24.3 
One Clarivate and other restructuring programs
— (0.1)— 
Total Lease abandonment costs
(1.1)3.6 24.3 
Restructuring costs
$19.6 $33.9 $66.7 
The following table summarizes the pre-tax charges by program and segment during the periods indicated:
Year Ended December 31,
202420232022
Academia & Government:
Value Creation Plan
$0.1 $— $— 
Segment Optimization7.0 4.8 — 
ProQuest Acquisition Integration
(0.1)9.1 26.5 
One Clarivate and other restructuring programs
— (0.1)9.7 
Total A&G
7.0 13.8 36.2 
Intellectual Property:
Value Creation Plan
0.5 — — 
Segment Optimization5.3 4.6 — 
ProQuest Acquisition Integration
— 4.6 15.3 
One Clarivate and other restructuring programs
— — 4.6 
Total IP
5.8 9.2 19.9 
Life Sciences & Healthcare:
Segment Optimization6.8 7.7 — 
ProQuest Acquisition Integration
— 3.2 7.6 
One Clarivate and other restructuring programs
— — 3.0 
Total LS&H
6.8 10.9 10.6 
Restructuring costs
$19.6 $33.9 $66.7 
The table below summarizes the changes in our restructuring reserves by activity during the periods indicated:
Severance and related benefit costs
Exit, disposal, and abandonment costs
Total
Reserve balance as of December 31, 2022$11.5 $0.1 $11.6 
Expenses recorded30.1 3.8 33.9 
Payments made(29.9)(2.5)(32.4)
Noncash items(5.8)— (5.8)
Reserve balance as of December 31, 2023$5.9 $1.4 $7.3 
Expenses recorded20.3 (0.7)19.6 
Payments made(22.4)(4.8)(27.2)
Noncash items(1.5)4.1 2.6 
Reserve balance as of December 31, 2024$2.3 $— $2.3 
v3.25.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision (Benefit) for Income Taxes by Jurisdiction
The components of the Provision (benefit) for income taxes by jurisdiction were as follows:
Year Ended December 31,
202420232022
Current
U.K.$2.3 $(1.2)$9.7 
U.S. Federal19.0 14.5 (1.1)
U.S. State3.1 4.4 2.8 
Other36.8 (40.8)25.4 
Total current61.2 (23.1)36.8 
Deferred
U.K.0.8 (0.4)2.2 
U.S. Federal
(20.0)(30.5)(56.0)
U.S. State(3.2)(4.4)(3.8)
Other44.1 (42.9)(8.1)
Total deferred
21.7 (78.2)(65.7)
Provision (benefit) for income taxes$82.9 $(101.3)$(28.9)
Schedule of Components of Income (Loss) Before Income Tax
The components of Income (loss) before income tax were as follows:
Year Ended December 31,
202420232022
U.K. income (loss)$(155.4)$(180.1)$174.7 
U.S. income (loss)(437.8)(477.9)(3,721.5)
Other income (loss)39.4 (354.5)(442.3)
Income (loss) before income tax$(553.8)$(1,012.5)$(3,989.1)
Schedule of Reconciliation of the Statutory Income Tax Rate to Effective Tax Rate The following table presents a reconciliation between the statutory U.K. income tax rate and our effective tax rate:
Year Ended December 31,
202420232022
Income (loss) before income tax$(553.8)$(1,012.5)$(3,989.1)
Provision (benefit) for income taxes82.9 (101.3)(28.9)
Statutory rate25.0 %23.5 %19.0 %
Effect of different tax rates(0.6)%— %1.5 %
BEAT(1.2)%(0.7)%(0.2)%
Change in tax law
(9.6)%— %— %
Valuation allowances
(2.2)%(4.4)%(15.2)%
Share-based compensation(2.4)%(1.3)%(0.2)%
Other permanent differences(1.2)%(0.6)%— %
Withholding tax(0.7)%(0.5)%— %
Uncertain tax positions
(0.9)%7.0 %0.4 %
Outside basis difference in foreign subsidiary
(1.6)%2.1 %(0.1)%
Impairments(18.8)%(15.4)%(6.0)%
Divestitures
(1.1)%— %1.3 %
Tax credits
1.8 %0.6 %0.1 %
Other(1.5)%(0.3)%0.1 %
Effective tax rate
(15.0)%10.0 %0.7 %
Schedule of Deferred Income Tax Assets and Liabilities
The tax effects of the significant components of temporary differences giving rise to our deferred income tax assets and liabilities were as follows:
December 31,
20242023
Accounts receivable$1.9 $3.6 
Accrued expenses12.2 12.2 
Deferred revenue0.9 2.0 
Partnerships outside basis difference
40.9 68.1 
Other assets24.0 44.4 
Debt issuance costs10.4 11.5 
Lease liabilities8.4 10.6 
Goodwill
527.4 567.1 
Operating losses and tax attributes835.4 717.9 
Total deferred tax assets1,461.5 1,437.4 
Valuation Allowances
(1,279.7)(1,256.6)
Net deferred tax assets181.8 180.8 
Other identifiable intangible assets, net(365.1)(338.9)
Other liabilities(20.9)(16.1)
Right-of-use assets
(5.4)(6.8)
Fixed assets, net(15.2)(21.9)
Total deferred tax liabilities(406.6)(383.7)
Net deferred tax liabilities$(224.8)$(202.9)
Deferred tax assets and liabilities are presented net in the Consolidated Balance Sheets if they are in the same jurisdiction. The components of the net deferred tax liability, as reported in the Consolidated Balance Sheets, were as follows:
December 31,
20242023
Deferred tax asset$48.5 $46.7 
Deferred tax liability(273.3)(249.6)
Net deferred tax liability$(224.8)$(202.9)
Summary of Valuation Allowance
The following table summarizes the changes in our deferred tax valuation allowance:
December 31,
202420232022
Beginning balance, January 1
$1,256.6 $1,179.3 $546.8 
Change charged to expense/(income)
31.1 51.4 657.5 
Change charged to CTA
(8.0)25.9 (17.0)
Change charged to goodwill
— — (8.0)
Ending balance, December 31
$1,279.7 $1,256.6 $1,179.3 
Summary of unrecognized tax benefits, excluding interest and penalties:
The following table summarizes our unrecognized tax benefits, excluding interest and penalties:
December 31,
202420232022
Beginning balance, January 1
$26.0 $83.8 $100.2 
Increases for tax positions taken in prior years3.3 1.1 2.9 
Increases for tax positions taken in the current year2.1 1.6 1.5 
Increases for acquisitions (recorded against goodwill)— — 1.4 
Decreases for tax positions taken in prior years(0.5)(54.1)(19.3)
Decreases related to settlements with tax authorities
— (6.2)— 
Decreases due to statute expirations(0.1)(0.2)(2.9)
Ending balance, December 31
$30.8 $26.0 $83.8 
v3.25.0.1
Earnings Per Share (Tables)
12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted EPS Computations for Ordinary Shares
The basic and diluted EPS computations for our ordinary shares are calculated as follows:
Year Ended December 31,
202420232022
Basic EPS
Net income (loss)
$(636.7)$(911.2)$(3,960.2)
Dividends on preferred shares31.3 75.4 75.4 
Net income (loss) attributable to ordinary shares$(668.0)$(986.6)$(4,035.6)
Weighted average shares, basic
693.6 671.6 676.1 
Basic EPS$(0.96)$(1.47)$(5.97)
Diluted EPS
Net income (loss) attributable to ordinary shares$(668.0)$(986.6)$(4,035.6)
Change in fair value of private placement warrants— — (197.6)
Net income (loss) attributable to ordinary shares, diluted$(668.0)$(986.6)$(4,233.2)
Weighted average shares, basic
693.6 671.6 676.1 
Weighted average effect of potentially dilutive shares
— — 2.5 
Weighted average shares, diluted
693.6 671.6 678.6 
Diluted EPS$(0.96)$(1.47)$(6.24)
v3.25.0.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table summarizes reportable segment revenues, expenses, and profit and provides a reconciliation of total reportable segment Adjusted EBITDA to Net income (loss) for the periods indicated:
Year Ended December 31,
202420232022
Academia & Government
Revenues
$1,326.4 $1,323.3 $1,280.1 
People-related costs
(349.7)(352.8)(379.1)
Royalties and other product costs
(248.5)(247.7)(253.1)
Technology costs
(80.5)(75.6)(69.6)
Outside service costs
(39.9)(43.0)(46.2)
Other costs
(44.0)(45.7)(46.6)
A&G Adjusted EBITDA
$563.8 $558.5 $485.5 
Intellectual Property
Revenues$811.4 $862.7 $927.1 
People-related costs(283.3)(277.7)(272.8)
Royalties and other product costs(76.1)(91.3)(113.5)
Technology costs(46.3)(44.6)(43.0)
Outside service costs(21.1)(22.7)(28.7)
Other costs(26.1)(26.0)(26.1)
IP Adjusted EBITDA
$358.5 $400.4 $443.0 
Life Sciences & Healthcare
Revenues$418.9 $442.8 $452.6 
People-related costs(190.8)(188.0)(170.0)
Royalties and other product costs(37.6)(43.5)(42.5)
Technology costs(27.1)(24.5)(21.6)
Outside service costs(13.0)(14.4)(20.6)
Other costs(12.3)(14.1)(13.7)
LS&H Adjusted EBITDA
$138.1 $158.3 $184.2 
Total Reportable Segments
Revenues$2,556.7 $2,628.8 $2,659.8 
People-related costs(823.8)(818.5)(821.9)
Royalties and other product costs(362.2)(382.5)(409.1)
Technology costs(153.9)(144.7)(134.2)
Outside service costs(74.0)(80.1)(95.5)
Other costs(82.4)(85.8)(86.4)
Total Reportable Segments Adjusted EBITDA$1,060.4 $1,117.2 $1,112.7 
Reconciliation to net income (loss)
Benefit (provision) for income taxes(82.9)101.3 28.9 
Depreciation and amortization(727.0)(708.3)(710.5)
Interest expense, net(283.4)(293.7)(270.3)
Share-based compensation expense(60.6)(108.9)(102.2)
Goodwill and intangible asset impairments(540.7)(979.9)(4,449.1)
Restructuring and lease impairments(19.6)(40.0)(66.7)
Fair value adjustment of warrants5.2 15.9 206.8 
Transaction related costs(17.9)(8.2)(14.2)
Other(1)
29.8 (6.6)304.4 
Net income (loss)$(636.7)$(911.2)$(3,960.2)
(1) Includes the net impact of unrealized foreign currency gains and losses and other items that do not reflect our ongoing operating performance. This amount includes a net gain on sale of $54.7 from divestitures in 2024, a gain of $49.4 related to a legal settlement in 2023, and a gain on sale of $278.5 from a divestiture in 2022. See Note 2 - Acquisitions and Divestitures and Note 17 - Commitments and Contingencies for further details.
Schedule of Assets by Geography
The following table summarizes our long-lived assets by geography, based on physical location. Long-lived assets consists of Property and equipment, net and Operating lease right-of-use assets and excludes Goodwill, Other intangible assets, net, Deferred income taxes, and Other assets.
Year Ended December 31,
20242023
U.S.
$35.0 $41.0 
U.K.
18.1 20.1 
India
18.9 9.1 
All other
35.1 36.6 
Total long-lived assets$107.1 $106.8 
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - General (Details)
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Accounting Policies [Abstract]    
Number of reportable segments | segment 3  
Restricted cash | $ $ 10.5 $ 12.9
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)
Dec. 31, 2024
Computer hardware  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment estimated useful lives 3 years
Furniture, fixtures, and equipment | Minimum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment estimated useful lives 5 years
Furniture, fixtures, and equipment | Maximum  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment estimated useful lives 7 years
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Internally Developed Software and Content (Details)
Dec. 31, 2024
Software Development  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 5 years
Purchased software  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 3 years
Content | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 2 years
Content | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 5 years
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Intangible Assets (Details)
Dec. 31, 2024
Customer relationships | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 2 years
Customer relationships | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 23 years
Technology and Content | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 2 years
Technology and Content | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 20 years
Software Development  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 5 years
Trade names and Other | Minimum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 2 years
Trade names and Other | Maximum  
Finite-Lived Intangible Assets [Line Items]  
Intangible assets estimated useful lives 18 years
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Revenue Recognition (Details) - Technology and content
12 Months Ended
Dec. 31, 2024
Minimum  
Finite-Lived Intangible Assets [Line Items]  
Commission fees amortization period 1 year
Maximum  
Finite-Lived Intangible Assets [Line Items]  
Commission fees amortization period 7 years
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Defined Contribution Plans (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]      
Defined contribution plan expense $ 37.3 $ 34.9 $ 30.5
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Accrued Expenses and Other Current Liabilites (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Accounting Policies [Abstract]    
Customer Refund Liability, Current $ 84.8 $ 62.0
Accrued royalty costs 79.3 75.4
Other accrued expenses and other current liabilities 146.0 177.8
Accrued expenses and other current liabilities $ 310.1 $ 315.2
v3.25.0.1
Nature of Operations and Summary of Significant Accounting Policies - Other Operating (Income) Expense, Net (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accounting Policies [Abstract]      
Gain on sale from divestitures $ 54.7 $ 0.0 $ 278.5
Gain on legal settlement 0.0 (49.4) 0.0
Net foreign exchange loss (gain) 4.2 38.9 (45.4)
Miscellaneous expense (income), net (1.3) (0.3) (0.9)
Other operating expense (income), net $ (51.8) $ (10.8) $ (324.8)
v3.25.0.1
Acquisitions and Divestitures - Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Oct. 31, 2022
Dec. 31, 2024
Dec. 31, 2024
Jun. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Business Acquisition [Line Items]              
Loss on divestiture         $ (54.7) $ 0.0 $ (278.5)
Finite-lived intangible assets   $ 8,284.3 $ 8,284.3   8,284.3 8,849.7  
Asset impairment charge   75.0          
Proceeds from divestitures, net of cash divested         84.4 10.5 285.0
Customer relationships              
Business Acquisition [Line Items]              
Finite-lived intangible assets   $ 6,258.0 6,258.0   6,258.0 6,642.7  
Disposal Group, Held-for-sale, Not Discontinued Operations | Valipat              
Business Acquisition [Line Items]              
Consideration for divestiture       $ 33.8      
Divestiture consideration period payable       10 years      
Contingent consideration receivable       $ 25.0      
Loss on divestiture         (14.8)    
Disposal group, Intangible assets       26.1      
Asset impairment charge           $ 132.2  
Disposal Group, Held-for-sale, Not Discontinued Operations | Valipat | Customer relationships              
Business Acquisition [Line Items]              
Finite-lived intangible assets       $ 158.3      
Discontinued Operations, Disposed of by Sale              
Business Acquisition [Line Items]              
Loss on divestiture         $ (54.7)   $ (278.5)
Discontinued Operations, Disposed of by Sale | MarkMonitor              
Business Acquisition [Line Items]              
Deferred closing consideration for divestiture $ 10.6            
People-related costs 278.5            
Proceeds from divestitures, net of cash divested $ 285.0            
Disposal Group, Disposed of by Sale, Not Discontinued Operations | ScholarOne Business              
Business Acquisition [Line Items]              
Proceeds from divestiture     103.6        
Gain on sale from divestitures     $ 69.5        
v3.25.0.1
Revenue - Disaggregated Revenues (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Revenues $ 2,556.7 $ 2,628.8 $ 2,659.8
North America [Member]      
Disaggregation of Revenue [Line Items]      
Revenues 1,381.4 1,405.5 1,462.3
EMEA [Member]      
Disaggregation of Revenue [Line Items]      
Revenues 667.8 707.5 698.3
Asia Pacific [Member]      
Disaggregation of Revenue [Line Items]      
Revenues 507.5 515.8 499.2
Subscription revenues      
Disaggregation of Revenue [Line Items]      
Revenues 1,626.8 1,618.1 1,618.8
Re-occurring Revenues      
Disaggregation of Revenue [Line Items]      
Revenues 429.8 444.6 441.9
Transactional and other revenues      
Disaggregation of Revenue [Line Items]      
Revenues $ 500.1 $ 566.1 $ 599.1
v3.25.0.1
Revenue - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue      
Revenue recognized that was deferred at the beginning of the period $ 868.2    
Prepaid expenses      
Disaggregation of Revenue      
Prepaid sales commissions 15.4 $ 19.7  
Noncurrent assets      
Disaggregation of Revenue      
Prepaid sales commissions $ 21.4 $ 23.8  
U.S. | Revenue | Customer Concentration Risk      
Disaggregation of Revenue      
Revenue from contract with customer 50.00% 49.00% 50.00%
v3.25.0.1
Revenue - Contract Balances (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]    
Accounts receivable, net $ 798.3 $ 908.3
Current portion of deferred revenues 859.1 983.1
Non-current portion of deferred revenues $ 16.6 $ 38.7
v3.25.0.1
Accounts Receivable - Components of Accounts Receivable (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Receivables [Abstract]        
Accounts receivable $ 814.5 $ 934.9    
Less: Accounts receivable allowance (16.2) (26.6) $ (27.1) $ (24.9)
Accounts receivable, net $ 798.3 $ 908.3    
v3.25.0.1
Accounts Receivable - Allowance (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]      
Balance at beginning of year $ 26.6 $ 27.1 $ 24.9
Additional provisions 3.2 7.0 10.9
Write-offs (12.9) (9.3) (7.8)
Exchange differences (0.7) 1.8 (0.9)
Balance at end of year $ 16.2 $ 26.6 $ 27.1
v3.25.0.1
Property and Equipment, Net (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Finance lease $ 8.0 $ 8.0  
Total property and equipment, gross 142.7 125.2  
Accumulated depreciation (89.2) (73.6)  
Property and equipment, net 53.5 51.6  
Depreciation 19.0 23.2 $ 35.2
Computer hardware      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross, excluding finance lease 64.3 54.5  
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross, excluding finance lease 21.6 15.9  
Furniture, fixtures and equipment      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross, excluding finance lease 46.6 44.5  
Other      
Property, Plant and Equipment [Line Items]      
Total property and equipment, gross, excluding finance lease $ 2.2 $ 2.3  
v3.25.0.1
Other Intangible Assets, Net and Goodwill - Intangible Assets by Major Class (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Goodwill And Intangible Assets [Line Items]    
Definite-lived intangible assets, Gross $ 11,671.7 $ 11,605.0
Definite-lived intangible assets, Accumulated Amortization (3,387.4) (2,755.3)
Definite-lived intangible assets, Net 8,284.3 8,849.7
Total intangible assets, Gross 11,828.6 11,761.9
Other intangible assets, net 8,441.2 9,006.6
Trade names    
Goodwill And Intangible Assets [Line Items]    
Indefinite-lived intangible assets: 156.9 156.9
Customer relationships    
Goodwill And Intangible Assets [Line Items]    
Definite-lived intangible assets, Gross 7,773.9 7,819.9
Definite-lived intangible assets, Accumulated Amortization (1,515.9) (1,177.2)
Definite-lived intangible assets, Net 6,258.0 6,642.7
Technology and content    
Goodwill And Intangible Assets [Line Items]    
Definite-lived intangible assets, Gross 2,748.8 2,798.3
Definite-lived intangible assets, Accumulated Amortization (1,204.6) (1,009.1)
Definite-lived intangible assets, Net 1,544.2 1,789.2
Computer software    
Goodwill And Intangible Assets [Line Items]    
Definite-lived intangible assets, Gross 1,060.6 897.9
Definite-lived intangible assets, Accumulated Amortization (609.2) (516.4)
Definite-lived intangible assets, Net 451.4 381.5
Trade names and other    
Goodwill And Intangible Assets [Line Items]    
Definite-lived intangible assets, Gross 88.4 88.9
Definite-lived intangible assets, Accumulated Amortization (57.7) (52.6)
Definite-lived intangible assets, Net $ 30.7 $ 36.3
v3.25.0.1
Other Intangible Assets, Net and Goodwill - Other Intangible Assets, Net Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Amortization of intangible assets           $ 708.0 $ 685.1 $ 675.3
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration]           Goodwill and intangible asset impairments Goodwill and intangible asset impairments  
Asset impairment charge $ 75.0              
Goodwill impairment           $ (465.7)    
IP Segment                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Goodwill impairment     $ (13.8)       $ (582.2)  
Life Sciences & Healthcare                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Goodwill impairment   $ (149.1)   $ (302.8)     (265.5)  
IP Reporting Unit and LS&H Reporting Unit | IP Segment and LS&H Segment                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Goodwill impairment         $ 844.7      
IP Reporting Unit | IP Segment                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Goodwill impairment         579.2      
LS&H Reporting Unit | Life Sciences & Healthcare                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Goodwill impairment         $ 265.5      
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group Within IP Segment                
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]                
Asset impairment charge             $ 132.2  
v3.25.0.1
Other Intangible Assets, Net and Goodwill - Remaining Weighted-Average Useful Life (Details)
12 Months Ended
Dec. 31, 2024
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]  
Remaining amortization period 16 years
Customer relationships  
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]  
Remaining amortization period 18 years
Technology and content  
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]  
Remaining amortization period 9 years
Computer software  
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]  
Remaining amortization period 6 years
Trade names and other  
Schedule Of Goodwill and Intangible Assets Disclosure [Line Items]  
Remaining amortization period 7 years
v3.25.0.1
Other Intangible Assets, net and Goodwill - Estimated Amortization (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2025 $ 680.2  
2026 646.9  
2027 612.9  
2028 581.3  
2029 538.1  
Thereafter 5,209.1  
Amortizing intangible assets 8,268.5  
Internally developed software projects in process 15.8  
Definite-lived intangible assets, Net $ 8,284.3 $ 8,849.7
v3.25.0.1
Other Intangible Assets, net and Goodwill - Change in the Carrying Amount of Goodwill (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Roll Forward]          
Goodwill, beginning balance       $ 2,023.7 $ 2,876.5
Acquisition       29.6 3.0
Goodwill impairment       (465.7)  
Goodwill impairment, excluding CTA impact         (847.7)
Impact of foreign currency fluctuations       (0.4) (8.1)
Divestiture       (20.6)  
Goodwill, ending balance $ 1,566.6     1,566.6 2,023.7
A&G Segment          
Goodwill [Roll Forward]          
Goodwill, beginning balance       1,109.8 1,109.8
Acquisition       0.0 0.0
Goodwill impairment       0.0 0.0
Impact of foreign currency fluctuations       (0.4) 0.0
Divestiture       (20.6)  
Goodwill, ending balance 1,088.8     1,088.8 1,109.8
IP Segment          
Goodwill [Roll Forward]          
Goodwill, beginning balance       0.0 590.3
Acquisition       13.8 0.0
Goodwill impairment   $ (13.8)     (582.2)
Impact of foreign currency fluctuations       0.0 (8.1)
Divestiture       0.0  
Goodwill, ending balance 0.0     0.0 0.0
Life Sciences & Healthcare          
Goodwill [Roll Forward]          
Goodwill, beginning balance       913.9 1,176.4
Acquisition       15.8 3.0
Goodwill impairment (149.1)   $ (302.8)   (265.5)
Impact of foreign currency fluctuations       0.0 0.0
Divestiture       0.0  
Goodwill, ending balance $ 477.8     477.8 $ 913.9
Life Sciences & Healthcare | Life Sciences & Healthcare          
Goodwill [Roll Forward]          
Goodwill impairment       $ (451.9)  
v3.25.0.1
Other Intangible Assets, net and Goodwill - Goodwill Narrative (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2024
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Goodwill [Line Items]              
Goodwill impairment           $ 465.7  
Goodwill impairment, excluding CTA impact             $ 847.7
Asset impairment charge $ 75.0            
Disposal Group, Held-for-sale, Not Discontinued Operations | Small Product Group Within IP Segment              
Goodwill [Line Items]              
Asset impairment charge             132.2
Disposal Group, Held-for-sale, Not Discontinued Operations | Valipat              
Goodwill [Line Items]              
Asset impairment charge             132.2
IP Segment              
Goodwill [Line Items]              
Goodwill impairment     $ 13.8       582.2
LS&H Segment              
Goodwill [Line Items]              
Goodwill impairment   $ 149.1   $ 302.8     265.5
A&G Segment              
Goodwill [Line Items]              
Goodwill impairment           $ 0.0 $ 0.0
IP Reporting Unit and LS&H Reporting Unit | IP Segment and LS&H Segment              
Goodwill [Line Items]              
Goodwill impairment         $ (844.7)    
IP Reporting Unit | IP Segment              
Goodwill [Line Items]              
Goodwill impairment         (579.2)    
IP Reporting Unit | IP Segment | Valipat              
Goodwill [Line Items]              
Goodwill impairment         3.0    
LS&H Reporting Unit | LS&H Segment              
Goodwill [Line Items]              
Goodwill impairment         $ (265.5)    
v3.25.0.1
Leases - Narrative (Details)
12 Months Ended
Dec. 31, 2024
contract
Leases [Abstract]  
Number of finance lease contracts 1
v3.25.0.1
Leases - Lease Cost and Other Information (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Lease Cost:      
Operating lease cost $ 20.2 $ 22.4 $ 27.9
Variable lease cost 4.0 5.3 2.5
Short-term lease cost 0.8 0.7 0.4
Finance lease cost:      
Amortization 0.3 0.5 10.8
Interest 2.1 2.1 1.2
Total lease cost 27.4 31.0 42.8
Cash paid for amounts included in measurement of lease liabilities      
Operating cash flows for operating leases 30.3 31.9 34.7
Operating cash flows for finance leases 2.1 2.1 1.2
Financing cash flows for finance leases 1.2 1.0 1.9
Right-of-use assets obtained in exchange for lease obligations      
Operating leases 16.8 16.2 2.6
Finance leases $ 0.0 $ 0.0 $ 2.4
Weighted-average remaining lease term      
Operating leases 5 years 5 years 5 years
Finance leases 12 years 13 years 14 years
Weighted-average discount rate      
Operating leases 6.20% 5.20% 4.30%
Finance leases 6.936% 6.936% 6.90%
v3.25.0.1
Leases - Future Lease Payments (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Operating Leases    
2025 $ 24.4  
2026 18.6  
2027 13.7  
2028 8.0  
2029 6.7  
Thereafter 15.3  
Total undiscounted cash flows 86.7  
Current lease liabilities 20.6 $ 24.4
Non-current lease liabilities 53.2 63.2
Total lease liabilities 73.8  
Interest on lease liabilities 12.9  
Finance Leases    
2025 3.3  
2026 3.4  
2027 3.4  
2028 3.5  
2029 3.6  
Thereafter 26.3  
Total undiscounted cash flows 43.5  
Current lease liabilities 1.3  
Non-current lease liabilities 28.0  
Total lease liabilities 29.3 $ 30.3
Interest on lease liabilities $ 14.2  
v3.25.0.1
Derivative Instruments - Narrative (Details)
€ in Millions, $ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2024
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Interest rate swap          
Derivative [Line Items]          
Notional value $ 750.8 $ 750.8      
Pre-tax gain expected to be reclassified within 12 months   8.8      
Cross currency swap | Net Investment Hedging | Designated as Hedging Instrument          
Derivative [Line Items]          
Notional value | €         € 100.0
Foreign Exchange Contract          
Derivative [Line Items]          
Notional value $ 91.1 91.1 $ 140.5    
Loss (gain) from the mark to market adjustment   $ 2.3 $ (0.8) $ 1.2  
Foreign Exchange Contract | Maximum          
Derivative [Line Items]          
Term of contract 180 days        
v3.25.0.1
Derivative Instruments - Fair Value (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Derivatives, Fair Value [Line Items]    
Asset Derivatives $ 18.4 $ 23.1
Liability Derivatives 1.1 2.1
Interest rate swap | Other current assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 0.0 4.1
Interest rate swap | Noncurrent assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 14.7 17.7
Cross currency swap | Noncurrent assets | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 3.7 0.0
Cross currency swap | Other non-current liabilities | Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives 0.0 2.0
Foreign currency forward | Not Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Asset Derivatives 0.0 1.3
Foreign currency forward | Accrued expenses and other current liabilities | Not Designated as Hedging Instrument    
Derivatives, Fair Value [Line Items]    
Liability Derivatives $ 1.1 $ 0.1
v3.25.0.1
Debt - Summary of Indebtedness (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]      
Finance lease, Effective Interest Rate 6.936% 6.936% 6.90%
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Long-term debt Long-term debt  
Finance lease, Carrying Value $ 29.3 $ 30.3  
Total debt outstanding 4,571.1 4,770.3  
Debt discounts and issuance costs (51.1) (48.0)  
Current portion of long-term debt (1.3) (1.2)  
Long-term debt $ 4,518.7 $ 4,721.1  
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued expenses and other current liabilities Accrued expenses and other current liabilities  
Senior Notes      
Debt Instrument [Line Items]      
Effective Interest Rate 4.875% 4.875%  
Carrying Value $ 921.4 $ 921.4  
Senior Secured Notes      
Debt Instrument [Line Items]      
Effective Interest Rate 3.875% 3.875%  
Carrying Value $ 921.2 $ 921.2  
Senior Secured Notes      
Debt Instrument [Line Items]      
Effective Interest Rate 4.50% 4.50%  
Carrying Value $ 700.0 $ 700.0  
Revolving Credit Facility      
Debt Instrument [Line Items]      
Effective Interest Rate 7.107% 8.206%  
Carrying Value $ 0.0 $ 0.0  
Term Loan Facility      
Debt Instrument [Line Items]      
Effective Interest Rate 7.107% 8.47%  
Carrying Value $ 1,999.2 $ 2,197.4  
v3.25.0.1
Debt - Senior Notes (2029) and Senior Secured Notes (2028) Additional Information (Details)
12 Months Ended
Dec. 31, 2024
Senior Notes (2029) and Senior Secured Notes (2028)  
Debt Instrument [Line Items]  
Redemption due to change in control (as a percent) 101.00%
v3.25.0.1
Debt - Senior Notes (2029) and Senior Secured Notes (2028) Redemption (Details)
12 Months Ended
Dec. 31, 2024
Senior Notes (2029) | Debt Instrument, Redemption, Period One  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 102.438%
Senior Notes (2029) | Debt Instrument, Redemption, Period Two  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 101.219%
Senior Notes (2029) | Debt Instrument, Redemption, Period Three  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 100.00%
Senior Secured Notes (2028) | Debt Instrument, Redemption, Period One  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 101.938%
Senior Secured Notes (2028) | Debt Instrument, Redemption, Period Two  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 100.969%
Senior Secured Notes (2028) | Debt Instrument, Redemption, Period Three  
Debt Instrument [Line Items]  
Redemption price (as a percentage of principal) 100.00%
v3.25.0.1
Debt - Senior Secured Notes (2026) (Details) - Senior Secured Notes
12 Months Ended
Dec. 31, 2024
Debt Instrument, Redemption  
Redemption price (as a percentage of principal) 100.00%
Redemption due to change in control (as a percent) 101.00%
v3.25.0.1
Debt - The Credit Facilities, Revolving Credit Facility and Term Loan Facility (2026) (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 31, 2024
Oct. 31, 2019
Jan. 31, 2024
Dec. 31, 2024
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Debt Instrument [Line Items]                
Repayment of long-term debt           $ 198.1 $ 300.0 $ 321.5
Level 2                
Debt Instrument [Line Items]                
Fair vale of company's debt       $ 4,423.2   4,423.2 4,615.3  
Revolving Credit Facility                
Debt Instrument [Line Items]                
Collateralized amount       7.7   7.7    
Revolving Credit Facility                
Debt Instrument [Line Items]                
Maximum borrowing capacity       700.0   700.0 $ 750.0  
Interest rate annual adjustment (as a percent)   3.25%            
Commitment fee percentage   0.50%            
Revolving Credit Facility | Prime                
Debt Instrument [Line Items]                
Interest rate spread (as a percent)   2.25%            
Revolving Credit Facility | Federal Funds Effective Swap Rate                
Debt Instrument [Line Items]                
Interest rate 2.75%   2.75%          
Interest rate spread (as a percent) 1.00%              
Revolving Credit Facility | Eurodollar                
Debt Instrument [Line Items]                
Interest rate 1.75%   1.75%          
Interest rate spread (as a percent) 1.00%              
Revolving Credit Facility | First Lien Leverage Ratios                
Debt Instrument [Line Items]                
Interest rate annual adjustment (as a percent)   2.75%            
Commitment fee percentage   0.375%            
Letter of credit                
Debt Instrument [Line Items]                
Maximum borrowing capacity       77.0   $ 77.0    
Term Loan Facility                
Debt Instrument [Line Items]                
Interest rate spread (as a percent)         3.00% 2.75%    
Repayment of long-term debt     $ 47.4 $ 140.0        
Debt face amount $ 2,150.0   $ 2,150.0          
Annual equivalent amortization percentage     1.00%          
v3.25.0.1
Debt - Amounts Due Under Outstanding Borrowings (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2025 $ 1.3  
2026 701.5  
2027 1.7  
2028 923.1  
2029 923.5  
Thereafter 2,020.0  
Total debt outstanding 4,571.1 $ 4,770.3
Less: capitalized debt issuance costs and original issue discount (51.1) $ (48.0)
Total, including the current portion of long-term debt $ 4,520.0  
v3.25.0.1
Shareholders' Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Jun. 03, 2024
Oct. 01, 2020
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
May 31, 2023
Feb. 28, 2022
Equity [Abstract]              
Preferred stock, outstanding (in shares) 14,400,000   0 14,400,000      
Preferred stock, dividend rate (as a percent) 5.25%   5.25%        
Stock Issued During Period, Shares, Conversion of Convertible Securities 55,300,000            
Preferred Stock, Convertible, Terms 3.8462            
Stock repurchase program, authorized amount     $ 500.0     $ 500.0 $ 1,000.0
Repurchase of ordinary shares (in shares)         10,700,000    
Repurchase of ordinary shares         $ 175.0    
Treasury stock acquired, average cost per share (in dollars per share)   $ 30.99 $ 5.81 $ 7.22 $ 16.33    
Treasury stock average price at retirement date (in dollars per share)         $ 15.61    
Stock repurchased and retired (in shares)     34,400,000 13,800,000      
Stock Repurchased and Retired During Period, Value     $ 200.0 $ (100.0) $ 175.0    
Sale of treasury shares (in shares)         500,000    
Treasury stock sold, average cost per share (in dollars per share)         $ 10.72    
Treasury stock sold at lower than repurchase price         $ 5.7    
v3.25.0.1
Shareholders' Equity - Accumulated Other Comprehensive Income (Loss) Roll forward (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of the period $ 5,992.3 $ 6,812.5 $ 11,925.9
Other comprehensive income (loss) before reclassifications (25.1) 208.0 (988.5)
Reclassifications from AOCI/ AOCL to net earnings (5.9) (37.4) (4.1)
Other comprehensive income (loss), net of tax (31.0) 170.6 (992.6)
Balance at end of the period 5,139.0 5,992.3 6,812.5
Accumulated Other Comprehensive Income (Loss)      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of the period (495.3) (665.9) 326.7
Other comprehensive income (loss), net of tax (31.0) 170.6 (992.6)
Balance at end of the period (526.3) (495.3) (665.9)
Interest rate swaps      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of the period 16.2 38.1 1.1
Other comprehensive income (loss) before reclassifications 16.1 14.9 41.1
Reclassifications from AOCI/ AOCL to net earnings (21.6) (36.8) (4.1)
Other comprehensive income (loss), net of tax (5.5) (21.9) 37.0
Balance at end of the period 10.7 16.2 38.1
Defined benefit pension plans      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of the period 0.4 1.5 (1.4)
Other comprehensive income (loss) before reclassifications (0.8) (1.1) 2.9
Reclassifications from AOCI/ AOCL to net earnings 0.0 0.0 0.0
Other comprehensive income (loss), net of tax (0.8) (1.1) 2.9
Balance at end of the period (0.4) 0.4 1.5
Foreign currency translation adjustment      
AOCI Attributable to Parent, Net of Tax [Roll Forward]      
Balance at beginning of the period (511.9) (705.5) 327.0
Other comprehensive income (loss) before reclassifications (40.4) 194.2 (1,032.5)
Reclassifications from AOCI/ AOCL to net earnings 15.7 (0.6) 0.0
Other comprehensive income (loss), net of tax (24.7) 193.6 (1,032.5)
Balance at end of the period $ (536.6) $ (511.9) $ (705.5)
v3.25.0.1
Private Placement Warrants - Narrative (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
Dec. 31, 2024
May 31, 2024
Dec. 31, 2023
Class of Warrant or Right [Line Items]      
Number of warrants expired (in shares)   17.8  
Warrant exercise price (usd per share)   $ 11.50  
Level 3 | Recurring      
Class of Warrant or Right [Line Items]      
Warrant outstanding $ 0.0   $ 5.1
v3.25.0.1
Share-based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Authorized grants (in shares) 60,000,000.0    
Total remaining unamortized compensation costs $ 0.0 $ 0.0  
Options      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Number of options, vested and exercisable at the end of the year (in shares) 1,900,000    
Vested and exercisable at the end of the year (in dollars per share) $ 12.60    
Weighted-average remaining contractual life 3 years 4 months 24 days    
RSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted average grant date fair value, granted (in dollars per share) $ 6.89 $ 10.34 $ 12.14
Vested in period, fair value $ 45.3 $ 62.4 $ 39.9
RSUs | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 1 year    
RSUs | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
PSUs      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Cliff vesting period 3 years    
Weighted average grant date fair value, granted (in dollars per share) $ 7.77 $ 13.55 $ 13.83
PSUs | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 3 years    
PSUs | Maximum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period 5 years    
Incentive Award Plan 2019      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Authorized grants (in shares) 20,700,000 26,800,000  
v3.25.0.1
Share-based Compensation - Share-based Compensation Expense (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total share based compensation expense $ 60.6 $ 108.9 $ 102.2
Provision (benefit) for income taxes (2.2) (8.7) (8.3)
Cost of revenues      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total share based compensation expense 14.6 39.9 36.3
Selling, general and administrative costs      
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]      
Total share based compensation expense $ 46.0 $ 69.0 $ 65.9
v3.25.0.1
Share-based Compensation - RSU and PSU Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
RSUs      
RSUs and PSUs      
Beginning of year (in shares) 10,800,000    
Granted (in shares) 9,100,000    
Exercised/Vested (in share) (6,600,000)    
Forfeited/Unexercised (in shares) (1,000,000.0)    
End of year (in shares) 12,300,000 10,800,000  
Total remaining unamortized compensation costs $ 38.0    
Weighted average remaining service period (in years) 10 months 28 days    
RSUs Weighted Average Grant Date Fair Value      
Weighted average grant date fair value, beginning balance (in dollars per share) $ 8.27 $ 11.89  
Weighted average grant date fair value, granted (in dollars per share) 6.89 10.34 $ 12.14
Weighted average grant date fair value, vested (in dollars per share) 12.10    
Weighted average grant date fair value, forfeited (in dollars per share) 9.55    
Ending balance (in dollars per share) $ 8.27 $ 11.89  
PSUs      
RSUs and PSUs      
Beginning of year (in shares) 2,800,000    
Granted (in shares) 2,600,000    
Exercised/Vested (in share) (300,000)    
Forfeited/Unexercised (in shares) (1,100,000)    
End of year (in shares) 4,000,000.0 2,800,000  
Total remaining unamortized compensation costs $ 11.4    
Weighted average remaining service period (in years) 1 year 6 months 29 days    
RSUs Weighted Average Grant Date Fair Value      
Weighted average grant date fair value, beginning balance (in dollars per share) $ 10.48 $ 12.95  
Weighted average grant date fair value, granted (in dollars per share) 7.77 13.55 $ 13.83
Weighted average grant date fair value, vested (in dollars per share) 15.15    
Weighted average grant date fair value, forfeited (in dollars per share) 9.10    
Ending balance (in dollars per share) $ 10.48 $ 12.95  
v3.25.0.1
Restructuring and Other Impairments (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   $ 19.6 $ 33.9 $ 66.7
Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]   Restructuring and other impairments Restructuring and other impairments Restructuring and other impairments
Restructuring Reserve [Roll Forward]        
Restructuring Reserve, Beginning Balance   $ 7.3 $ 11.6  
Expenses recorded   19.6 33.9 $ 66.7
Payments made   (27.2) (32.4)  
Noncash items   2.6 (5.8)  
Restructuring Reserve, Ending Balance $ 7.3 2.3 7.3 11.6
Impairment charge on equity investments 6.1      
Academia & Government        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   7.0 13.8 36.2
Restructuring Reserve [Roll Forward]        
Expenses recorded   7.0 13.8 36.2
Intellectual Property        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   5.8 9.2 19.9
Restructuring Reserve [Roll Forward]        
Expenses recorded   5.8 9.2 19.9
Life Sciences & Healthcare        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   6.8 10.9 10.6
Restructuring Reserve [Roll Forward]        
Expenses recorded   6.8 10.9 10.6
Severance and related benefit costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   20.3 30.1 39.2
Restructuring Reserve [Roll Forward]        
Restructuring Reserve, Beginning Balance   5.9 11.5  
Expenses recorded   20.3 30.1 39.2
Payments made   (22.4) (29.9)  
Noncash items   (1.5) (5.8)  
Restructuring Reserve, Ending Balance 5.9 2.3 5.9 11.5
Exit and disposal costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.4 0.2 3.2
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.4 0.2 3.2
Lease abandonment costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   (1.1) 3.6 24.3
Restructuring Reserve [Roll Forward]        
Expenses recorded   (1.1) 3.6 24.3
Exit, Disposal and Abandonment Costs        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   (0.7) 3.8  
Restructuring Reserve [Roll Forward]        
Restructuring Reserve, Beginning Balance   1.4 0.1  
Expenses recorded   (0.7) 3.8  
Payments made   (4.8) (2.5)  
Noncash items   4.1 0.0  
Restructuring Reserve, Ending Balance $ 1.4 0.0 1.4 0.1
Segment Optimization Program | Academia & Government        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   7.0 4.8 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   7.0 4.8 0.0
Segment Optimization Program | Intellectual Property        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   5.3 4.6 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   5.3 4.6 0.0
Segment Optimization Program | Life Sciences & Healthcare        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   6.8 7.7 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   6.8 7.7 0.0
Segment Optimization Program | Severance and related benefit costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   19.9 13.4 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   19.9 13.4 0.0
Segment Optimization Program | Exit and disposal costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.3 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.3 0.0 0.0
Segment Optimization Program | Lease abandonment costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   (1.1) 3.7 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   (1.1) 3.7 0.0
ProQuest Acquisition Integration Program | Academia & Government        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   (0.1) 9.1 26.5
Restructuring Reserve [Roll Forward]        
Expenses recorded   (0.1) 9.1 26.5
ProQuest Acquisition Integration Program | Intellectual Property        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 4.6 15.3
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 4.6 15.3
ProQuest Acquisition Integration Program | Life Sciences & Healthcare        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 3.2 7.6
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 3.2 7.6
ProQuest Acquisition Integration Program | Severance and related benefit costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   (0.1) 16.7 22.9
Restructuring Reserve [Roll Forward]        
Expenses recorded   (0.1) 16.7 22.9
ProQuest Acquisition Integration Program | Exit and disposal costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.2 2.2
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.2 2.2
ProQuest Acquisition Integration Program | Lease abandonment costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 24.3
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.0 24.3
Other Restructuring Plans | Academia & Government        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 (0.1) 9.7
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 (0.1) 9.7
Other Restructuring Plans | Intellectual Property        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 4.6
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.0 4.6
Other Restructuring Plans | Life Sciences & Healthcare        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 3.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.0 3.0
Other Restructuring Plans | Severance and related benefit costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 16.3
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.0 16.3
Other Restructuring Plans | Exit and disposal costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 1.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 0.0 1.0
Other Restructuring Plans | Lease abandonment costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 (0.1) 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.0 (0.1) 0.0
Value Creation Plan        
Restructuring Cost and Reserve [Line Items]        
Expected additional restructuring costs   30.0    
Value Creation Plan | Academia & Government        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.1 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.1 0.0 0.0
Value Creation Plan | Intellectual Property        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.5 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.5 0.0 0.0
Value Creation Plan | Severance and related benefit costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.5 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.5 0.0 0.0
Value Creation Plan | Exit and disposal costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.1 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   0.1 0.0 0.0
Value Creation Plan | Lease abandonment costs:        
Restructuring Cost and Reserve [Line Items]        
Restructuring charges excluding impairment of investments   0.0 0.0 0.0
Restructuring Reserve [Roll Forward]        
Expenses recorded   $ 0.0 $ 0.0 $ 0.0
v3.25.0.1
Income Taxes - Provision (Benefit) for Income Taxes by Jurisdiction (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Current Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.K. $ 2.3 $ (1.2) $ 9.7
Other 36.8 (40.8) 25.4
Total current 61.2 (23.1) 36.8
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.K. 0.8 (0.4) 2.2
Other 44.1 (42.9) (8.1)
Total deferred 21.7 (78.2) (65.7)
Provision (benefit) for income taxes 82.9 (101.3) (28.9)
U.S. Federal      
Current Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.S. 19.0 14.5 (1.1)
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.S. (20.0) (30.5) (56.0)
US State      
Current Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.S. 3.1 4.4 2.8
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]      
U.S. $ (3.2) $ (4.4) $ (3.8)
v3.25.0.1
Income Taxes - Components of Income (Loss) Before Income Tax (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.K. income (loss) $ (155.4) $ (180.1) $ 174.7
U.S. income (loss) (437.8) (477.9) (3,721.5)
Other income (loss) 39.4 (354.5) (442.3)
Income (loss) before income tax $ (553.8) $ (1,012.5) $ (3,989.1)
v3.25.0.1
Income Taxes - Reconciliation of the Statutory Income Tax Rate to Effective Tax Rate (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Income (loss) before income tax $ (553.8) $ (1,012.5) $ (3,989.1)
Provision (benefit) for income taxes $ 82.9 $ (101.3) $ (28.9)
RATE      
Statutory rate 25.00% 23.50% 19.00%
Effect of different tax rates (0.60%) 0.00% 1.50%
BEAT (1.20%) (0.70%) (0.20%)
Tax rate modifications (9.60%) 0.00% 0.00%
Valuation allowances (2.20%) (4.40%) (15.20%)
Share-based compensation (2.40%) (1.30%) (0.20%)
Other permanent differences (1.20%) (0.60%) 0.00%
Withholding tax (0.70%) (0.50%) 0.00%
Uncertain tax positions (0.90%) 7.00% 0.40%
Outside basis difference in foreign subsidiary (1.60%) 2.10% (0.10%)
Impairments (18.80%) (15.40%) (6.00%)
Divestitures (1.10%) 0.00% 1.30%
Tax credits 1.80% 0.60% 0.10%
Other (1.50%) (0.30%) 0.10%
Effective tax rate (15.00%) 10.00% 0.70%
New corporate income tax rate $ 53.9    
Tax (benefit) due to release in valuation allowance 23.1 $ 77.3  
Income tax benefit due to impairment of intangible assets 16.6 33.0  
Income tax benefit due to impairment of goodwill $ 14.2 22.7  
Tax (benefit) on settlement of tax dispute   $ (70.4)  
v3.25.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Line Items]        
Provision (benefit) for income taxes $ 82.9 $ (101.3) $ (28.9)  
New corporate income tax rate 53.9      
Income tax benefit due to change in deferred tax assets valuation allowance (23.1) (77.3)    
Income tax benefit due to impairment of intangible assets 16.6 33.0    
Income tax benefit due to impairment of goodwill 14.2 22.7    
Tax (benefit) on settlement of tax dispute   (70.4)    
Establishment of valuation allowance 10.2      
Release of valuation allowances   21.2    
Valuation allowances 1,279.7 1,256.6 1,179.3 $ 546.8
Tax credit carryforwards 25.5      
Deferred taxes on undistributed earnings of foreign subsidiaries 12.5      
Unrecognized Tax Benefits 30.8 26.0 83.8 $ 100.2
Accrued interest and penalties on uncertain tax positions 3.2 2.6    
Interest and penalties recognized on uncertain tax positions 0.7 $ (23.2) $ 3.0  
Internal Revenue Service (IRS)        
Income Tax Disclosure [Line Items]        
Operating loss carryforwards 1,698.8      
Her Majesty's Revenue and Customs (HMRC)        
Income Tax Disclosure [Line Items]        
Operating loss carryforwards 475.0      
US State        
Income Tax Disclosure [Line Items]        
Operating loss carryforwards 923.5      
National Tax Agency, Japan        
Income Tax Disclosure [Line Items]        
Operating loss carryforwards 40.4      
All Other Foreign Jurisdictions        
Income Tax Disclosure [Line Items]        
Operating loss carryforwards $ 145.9      
v3.25.0.1
Income Taxes - Tax effects of the significant components of temporary differences (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]        
Accounts receivable $ 1.9 $ 3.6    
Accrued expenses 12.2 12.2    
Deferred revenue 0.9 2.0    
Partnerships outside basis difference 40.9 68.1    
Other assets 24.0 44.4    
Debt issuance costs 10.4 11.5    
Lease liabilities 8.4 10.6    
Goodwill 527.4 567.1    
Operating losses and tax attributes 835.4 717.9    
Total deferred tax assets 1,461.5 1,437.4    
Valuation Allowances (1,279.7) (1,256.6) $ (1,179.3) $ (546.8)
Net deferred tax assets 181.8 180.8    
Other identifiable intangible assets, net (365.1) (338.9)    
Other liabilities (20.9) (16.1)    
Right-of-use assets (5.4) (6.8)    
Fixed assets, net (15.2) (21.9)    
Total deferred tax liabilities (406.6) (383.7)    
Net deferred tax liabilities $ (224.8) $ (202.9)    
v3.25.0.1
Income taxes - Deferred Income Tax Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Income Tax Disclosure [Abstract]    
Deferred tax asset $ 48.5 $ 46.7
Deferred tax liability (273.3) (249.6)
Net deferred tax liabilities $ (224.8) $ (202.9)
v3.25.0.1
Income Taxes - Deferred Tax Valuation Allowance (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Valuation Allowance [Roll Forward]      
Beginning balance, January 1 $ 1,256.6 $ 1,179.3 $ 546.8
Change charged to expense/(income) 31.1 51.4 657.5
Change charged to CTA (8.0) 25.9 (17.0)
Change charged to goodwill 0.0 0.0 (8.0)
Ending balance, December 31 $ 1,279.7 $ 1,256.6 $ 1,179.3
v3.25.0.1
Income Taxes - Uncertain Tax Positions (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
Accrued interest and penalties on uncertain tax positions $ 3.2 $ 2.6  
Interest and penalties recognized on uncertain tax positions 0.7 (23.2) $ 3.0
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Beginning balance 26.0 83.8 100.2
Increases for tax positions taken in prior years 3.3 1.1 2.9
Increases for tax positions taken in the current year 2.1 1.6 1.5
Increases for acquisitions (recorded against goodwill) 0.0 0.0 1.4
Decreases for tax positions taken in prior years (0.5) (54.1) (19.3)
Decreases related to settlements with tax authorities 0.0 (6.2) 0.0
Decreases due to statute expirations (0.1) (0.2) (2.9)
Ending balance 30.8 $ 26.0 $ 83.8
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit $ 1.2    
v3.25.0.1
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Basic EPS      
Net income (loss) $ (636.7) $ (911.2) $ (3,960.2)
Dividends on preferred shares 31.3 75.4 75.4
Net income (loss) attributable to ordinary shares $ (668.0) $ (986.6) $ (4,035.6)
Weighted average shares, basic (in shares) 693.6 671.6 676.1
Basic EPS (in dollars per share) $ (0.96) $ (1.47) $ (5.97)
Diluted EPS      
Net income (loss) attributable to ordinary shares $ (668.0) $ (986.6) $ (4,035.6)
Change in fair value of private placement warrants 0.0 0.0 (197.6)
Net income (loss) attributable to ordinary shares, diluted $ (668.0) $ (986.6) $ (4,233.2)
Weighted average shares, basic (in shares) 693.6 671.6 676.1
Weighted average effect of potentially dilutive shares (in shares) 0.0 0.0 2.5
Weighted average shares, diluted (in shares) 693.6 671.6 678.6
Diluted EPS (in dollars per share) $ (0.96) $ (1.47) $ (6.24)
v3.25.0.1
Earnings Per Share - Narrative (Details) - shares
shares in Millions
12 Months Ended
Jun. 03, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Preferred stock, dividend rate (as a percent) 5.25% 5.25%    
Warrant and share-based payment awards        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive shares (in shares)   20.2 32.7 11.0
v3.25.0.1
Segment Information - Narrative (Details)
12 Months Ended
Dec. 31, 2024
segment
Segment Reporting [Abstract]  
Number of reportable segments 3
v3.25.0.1
Segment Information - Revenue by Reportable Segment (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue      
Total Revenues $ 2,556.7 $ 2,628.8 $ 2,659.8
People-related costs (823.8) (818.5) (821.9)
Royalties and other product costs (362.2) (382.5) (409.1)
Technology costs (153.9) (144.7) (134.2)
Outside service costs (74.0) (80.1) (95.5)
Other costs (82.4) (85.8) (86.4)
Adjusted EBITDA 1,060.4 1,117.2 1,112.7
Provision (benefit) for income taxes (82.9) 101.3 28.9
Depreciation and amortization (727.0) (708.3) (710.5)
Interest expense, net (283.4) (293.7) (270.3)
Royalties and other product costs (60.6) (108.9) (102.2)
Goodwill and intangible asset impairments (540.7) (979.9) (4,449.1)
Restructuring and other impairments (19.6) (40.0) (66.7)
Mark to market gain (loss) on financial instruments 5.2 15.9 206.8
Transaction related costs (17.9) (8.2) (14.2)
Other 29.8 (6.6) 304.4
Net income (loss) (636.7) (911.2) (3,960.2)
Academia & Government      
Disaggregation of Revenue      
Total Revenues 1,326.4 1,323.3 1,280.1
People-related costs (349.7) (352.8) (379.1)
Royalties and other product costs (248.5) (247.7) (253.1)
Technology costs (80.5) (75.6) (69.6)
Outside service costs (39.9) (43.0) (46.2)
Other costs (44.0) (45.7) (46.6)
Adjusted EBITDA 563.8 558.5 485.5
Intellectual Property      
Disaggregation of Revenue      
Total Revenues 811.4 862.7 927.1
People-related costs (283.3) (277.7) (272.8)
Royalties and other product costs (76.1) (91.3) (113.5)
Technology costs (46.3) (44.6) (43.0)
Outside service costs (21.1) (22.7) (28.7)
Other costs (26.1) (26.0) (26.1)
Adjusted EBITDA 358.5 400.4 443.0
Life Sciences & Healthcare      
Disaggregation of Revenue      
Total Revenues 418.9 442.8 452.6
People-related costs (190.8) (188.0) (170.0)
Royalties and other product costs (37.6) (43.5) (42.5)
Technology costs (27.1) (24.5) (21.6)
Outside service costs (13.0) (14.4) (20.6)
Other costs (12.3) (14.1) (13.7)
Adjusted EBITDA $ 138.1 $ 158.3 $ 184.2
v3.25.0.1
Segment Information - Assets by Geography (Details) - USD ($)
$ in Millions
Dec. 31, 2024
Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 107.1 $ 106.8
U.S.    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 35.0 41.0
U.K.    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 18.1 20.1
India    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets 18.9 9.1
All other    
Revenues from External Customers and Long-Lived Assets [Line Items]    
Total long-lived assets $ 35.1 $ 36.6
v3.25.0.1
Commitments and Contingencies (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Loss Contingencies [Line Items]      
Gain on settlement $ 0.0 $ 49.4 $ 0.0
One of the larger legal claims      
Loss Contingencies [Line Items]      
Gain on settlement   $ 49.4